Vaccinogen (VGEN) Inactive 10-K15 Apr 152014 FY Annual reportFinancial data

Company Profile

Document_And_Entity_Informatio

Document And Entity Information (USD $)	12 Months Ended
Document And Entity Information (USD $)	Dec. 31, 2014	Mar. 24, 2015	Jun. 30, 2014
Document Information [Line Items]
Document Type	10-K
Amendment Flag	FALSE
Document Period End Date	31-Dec-14
Document Fiscal Year Focus	2014
Document Fiscal Period Focus	FY
Entity Registrant Name	VACCINOGEN INC
Entity Central Index Key	1453001
Current Fiscal Year End Date	-19
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$46,880,000
Trading Symbol	VGEN
Entity Common Stock, Shares Outstanding		35,986,752

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current Assets
Cash and cash equivalents	$3,040,942	$73,096
Restricted cash	39,563	44,394
Inventory	99,250	100,150
Prepaid expenses and other current assets	2,910,476	115,522
Total Current Assets	6,090,231	333,162
Long-Term Assets
Prepaid income taxes	8,575,810	0
Property and equipment, net	393,046	198,790
Intangible assets, net	56,022,289	62,725,559
Total Long-Term Assets	64,991,145	62,924,349
Total Assets	71,081,376	63,257,511
Liabilities and Stockholders' Equity
Accounts payable	2,709,551	3,357,287
Financial instruments	1,798,184	11,794,790
Accrued compensation	653,294	1,108,541
Accrued expenses and other liabilities	374,106	639,448
Notes payable	0	4,831,217
Accrued interest	0	863,637
Related party payable	0	54,099
Total Current Liabilities	5,535,135	22,649,019
Long-Term Liabilities
Income tax payable	8,814,027	0
Notes payable	3,000,000	0
Accrued interest	856,666	0
Total Long-Term Liabilities	12,670,693	0
Total Liabilities	18,205,828	22,649,019
Commitments and Contigencies
Stockholders' Equity
Preferred stock, $0.0001 par value: 50,000,000 shares authorized; 0 shares issued and oustanding	0	0
Common stock, $0.0001 par value; 200,000,000 shares authorized; 34,962,172 and 31,568,629 shares issued and outstanding at December 31, 2014 and December 31, 2013, respectively.	3,496	3,157
Additional paid-in capital	164,844,066	143,920,855
Accumulated other comprehensive loss	-165,888	-36,199
Accumulated deficit	-111,806,126	-103,279,321
Total Stockholders' Equity	52,875,548	40,608,492
Total Liabilities and Stockholders' Equity	$71,081,376	$63,257,511

Consolidated_Balance_Sheets_Pa

Consolidated Balance Sheets (Parenthetical) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Preferred stock, par value (in dollars per share)	$0.00	$0.00
Preferred Stock, Shares Authorized	50,000,000	50,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Common stock, par value (in dollars per share)	$0.00	$0.00
Common Stock, Shares Authorized	200,000,000	200,000,000
Common Stock, Shares, Issued	34,962,172	31,568,629
Common Stock, Shares, Outstanding	34,962,172	31,568,629

Consolidated_Statements_of_Ope

Consolidated Statements of Operations (USD $)	12 Months Ended
Consolidated Statements of Operations (USD $)	Dec. 31, 2014	Dec. 31, 2013
Revenues	$0	$0
Operating Expenses:
Research and development	9,092,072	8,687,406
General and administrative expenses	5,739,370	10,756,150
Total Operating Expenses	14,831,442	19,443,556
Loss From Operations	-14,831,442	-19,443,556
Gain (loss) on Financial Instruments	7,753,694	-3,074,600
Interest Expense and Other Expenses	-1,210,840	-2,062,385
Net Loss Before Income Taxes	-8,288,588	-24,580,541
Provision for income taxes	-238,217	0
Net Loss	-8,526,805	-24,580,541
Net loss available to commmon stockholders	($8,526,805)	($24,580,541)
Net loss per Common Share
Basic (in dollars per share)	($0.26)	($0.79)
Diluted (in dollars per share)	($0.50)	($0.79)
Weighted average shares
Basic (in shares)	32,760,479	31,089,148
Diluted (in shares)	32,760,479	31,089,148

Consolidated_Statements_of_Com

Consolidated Statements of Comprehensive Loss (USD $)	12 Months Ended
Consolidated Statements of Comprehensive Loss (USD $)	Dec. 31, 2014	Dec. 31, 2013
Comprehensive Loss
Net loss	($8,526,805)	($24,580,541)
Foreign currency translation adjustments	-129,689	46,953
Total Comprehensive Loss	($8,656,494)	($24,533,588)

Consolidated_Statements_of_Cha

Consolidated Statements of Changes in Stockholders' Equity (USD $)	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Beginning Balance at Dec. 31, 2012	$59,339,552	$3,060	$138,118,424	($78,698,780)	($83,152)
Beginning Balance (in shares) at Dec. 31, 2012		30,601,700
Issuance of common stock for cash	3,253,316	80	3,253,236	0	0
Issuance of common stock for cash (in shares)		796,389
Contingent Warrants	1,751,108	0	1,751,108	0	0
Conversion of 2012 Bridge Loan for common stock	751,561	17	751,544	0	0
Conversion of 2012 Bridge Loan for common stock (in shares)		170,540
Stock-based compensation	46,543	0	46,543	0	0
Other comprehensive income	46,953	0	0	0	46,953
Net loss	-24,580,541	0	0	-24,580,541	0
Ending Balance at Dec. 31, 2013	40,608,492	3,157	143,920,855	-103,279,321	-36,199
Ending Balance (in shares) at Dec. 31, 2013		31,568,629
Issuance of common stock for cash	15,200,689	333	15,200,356	0	0
Issuance of common stock for cash (in shares)		3,332,795
Investment option reclassification	3,168,224	0	3,168,224	0	0
Contingent Warrants	1,818,642	0	1,818,642	0	0
Conversion of 2012 Bridge Loan for common stock	227,939	6	227,933	0	0
Conversion of 2012 Bridge Loan for common stock (in shares)		56,075
Stock-based compensation	86,943	0	86,943	0	0
Stock-based compensation warrants and modifications	402,147	0	402,147	0	0
Conversion of payable to common stock	18,966	0	18,966	0	0
Conversion of payable to common stock (in shares)		4,673
Other comprehensive income	-129,689	0	0	0	-129,689
Net loss	-8,526,805	0	0	-8,526,805	0
Ending Balance at Dec. 31, 2014	$52,875,548	$3,496	$164,844,066	($111,806,126)	($165,888)
Ending Balance (in shares) at Dec. 31, 2014		34,962,172

Consolidated_Statements_of_Cas

Consolidated Statements of Cash Flows (USD $)	12 Months Ended
Consolidated Statements of Cash Flows (USD $)	Dec. 31, 2014	Dec. 31, 2013
Cash Flows From Operating Activities
Net loss	($8,526,805)	($24,580,541)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	51,723	24,165
Gain on extinguishment of debt	-500,000	0
Amortization of intangible assets	6,703,270	6,703,272
(Gain) Loss on financial instruments	-7,753,694	3,074,600
Other stock based expense	402,147	5,954,545
Stock based compensation - employees	86,943	46,543
Non-cash interest expense	1,818,642	1,751,108
Changes in accrued and prepaid taxes	238,217	0
Changes in operating assets and liabilities, net:
Accrued interest	-6,971	-66,278
Changes in restricted cash	4,831	-576
Prepaid expenses and other assets	-2,793,932	1,356,113
Accounts payable and accrued expenses and liabilities	-1,349,358	2,018,939
Net Cash Used In Operating Activities	-11,624,987	-3,718,110
Cash Flows From Investing Activities
Purchases of property and equipment	-241,827	-116,087
Net Cash Used In Investing Activities	-241,827	-116,087
Cash Flows From Financing Activities:
Proceeds from issuance of common stock and warrants net of issuance costs	17,153,939	4,179,893
Repayments of related party notes payable	-54,099	20,000
Repayments of Abell Loan and Bridge Loan	-2,131,217	-468,783
Net Cash Provided by Financing Activities	14,968,623	3,731,110
Impact of foreign currency translation on cash and cash equivalents	-133,963	62,343
Net Increase (Decrease) in Cash and Cash Equivalents	2,967,846	-40,744
Cash and Cash Equivalents, beginning of period	73,096	113,840
Cash and Cash Equivalents, end of period	$3,040,942	$73,096

Organization

Organization	12 Months Ended
Organization	Dec. 31, 2014
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Operations [Text Block]	1. Organization

	The Business

	Vaccinogen, Inc. (the “Company” or “Vaccinogen”), a biotechnology Company headquartered in Baltimore, Maryland, was incorporated in the State of Delaware during 2007 for the purpose of developing therapies and vaccines to combat cancer by using the body’s own immune system. On November 23, 2010, the Company changed its domicile from Delaware to Maryland by means of a merger of the Company with and into its wholly owned subsidiary Vaccinogen I, Inc., a Maryland corporation.

	On October 10, 2007, the Company entered into a license agreement with Intracel Holdings Corporation (“Intracel”), a related party, for the exclusive and indefinite rights to use the OncoVAX® technology platform. OncoVAX® is an active specific immunotherapy (“ASI”) that uses the patient’s own cancer cells to create a vaccine that in turn is used to block the return of cancer following surgery. On October 23, 2007, Vaccinogen acquired out of bankruptcy, certain tangible assets that had been previously owned and used by Intracel’s wholly owned subsidiary in the Netherlands. These assets will be used to conduct research and development and in the commercialization of OncoVAX® to produce vaccines. In connection with the acquisition of these assets, the Company formed, Vaccinogen BV, for the purposes of continuing development of OncoVAX®. In June 2010, the Company entered into an agreement with Intracel (the “Asset Transfer Agreement”) whereby the Company acquired title to the patents associated with the OncoVAX® (See Note 4).

	During September 2014 three new-wholly owned entities were formed by Vaccinogen. The three entities are Vaccinogen (US) R&D, Inc. a Delaware corporation; Vaccinogen International Partners, LP, a Bermuda partnership and Vaccinogen Bermuda, Ltd., a Bermuda company. The purpose of the entities is to facilitate the global commercialization of OncoVAX® and other products as they are developed and marketed by the Company.

Going_Concern

Going Concern	12 Months Ended
	Dec. 31, 2014
Going Concern [Abstract]
Going Concern [Text Block]	2	Going Concern

	The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has recurring losses and as of December 31, 2014, the Company had an accumulated deficit of approximately $112 million and nominal working capital of less than $1 million. The Company expects to incur additional losses in the future in connection with research and development activities. Since inception, the Company has financed its activities principally from the issuance of equity and debt securities and loans from officers.

	The Company’s ability to continue as a going concern is dependent upon the Company’s ability to raise additional debt and equity capital. There can be no assurance that such capital will be available in sufficient amounts or on terms acceptable to the Company. These factors raise substantial doubt about the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments relating to the recoverability of the recorded assets or the classification of liabilities that may be necessary should the Company be unable to continue as a going concern.

	The Company does not have sufficient capital to fund its plan of operations over the next twelve months. In order to address its capital needs, including its planned phase IIIb clinical trial, the Company is actively pursuing additional equity financing, in the form of either a private placement or a public offering. The Company has been in ongoing discussions with strategic institutional investors and investment banks with respect to such possible offerings.

	In April 2014, the Company entered into a binding agreement (as amended, the “TIS Agreement”) with a Stockholm-based investor group known as The Investment Syndicate (“TIS”) under which TIS agreed to purchase up to $80 million of the Company’s common stock. A total of $20 million in equity financing has closed since April 2014 following Vaccinogen’s satisfaction of certain closing conditions. The remaining $60 million will be paid in three separate closings upon completion of certain milestones.

	The Company has received repeated assurances from a TIS representative that TIS fully intends to meet its obligations under the TIS Agreement. Specifically, on November 11, 2014, the Company received a letter from TIS indicating a desire on the part of TIS to invest the remaining $60,000,000 shortly after consummation of the second closing (with the final $20,000,000 to be held in escrow pending fulfillment of the milestone contained in the TIS Agreement relating to the first patient receiving the first three doses of OncoVax, with positive results). Since receipt of that letter, an additional $10,000,000 investment has been consummated by a TIS member without any further investments from TIS members. In more recent communications from TIS, a TIS representative acknowledged that the Company has met the conditions for funding of at least $20,000,000 and re-confirmed that TIS fully intends to meet its obligations under the TIS Agreement to fund the remaining TIS committed investment notwithstanding any conditions to closing. However, the TIS representative has informed the Company that the timing of TIS funding continues to be dependent upon funds TIS members expect to receive from a third party relating to investments made and services provided by TIS members. Notwithstanding these verbal and written assurances from TIS, the Company has been unable to verify the validity of the TIS assurances, the availability of the funds TIS members anticipate using to satisfy their obligations, the timing of the receipt of the funds, or the reliability of the third party from which TIS members expect to receive funds. As of the date hereof, the TIS members' option to invest an additional $30,000,000 (on top of the $80,000,000 committed investment) has expired.

	Adequate financing opportunities might not be available to the Company, when and if needed, on acceptable terms or at all. If the Company is unable to obtain additional financing in sufficient amounts or on acceptable terms under such circumstances or if the Company fails to consummate the additional closings under the TIS Agreement, the Company’s operating results and prospects will be adversely affected.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2014
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	3. Summary of Significant Accounting Policies

	Principles of Consolidation

	The consolidated financial statements include the accounts of Vaccinogen, Inc. and its direct or indirect wholly owned subsidiaries, Vaccinogen BV (a company incorporated in the Netherlands); Vaccinogen (US) R&D, Inc.; Vaccinogen International Partners, LP; and Vaccinogen Bermuda, Ltd. All intercompany balances and transactions have been eliminated in consolidation.

	New Accounting Standards

	In September 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The amendments in this Update define when and how companies are required to disclose going concern uncertainties, which must be evaluated each interim and annual period. Specifically, the ASU requires management to determine whether substantial doubt exists regarding the entity’s going concern presumption. Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). If substantial doubt exists, certain disclosures are required; the extent of those disclosures depends on an evaluation of management’s plans (if any) to mitigate the going concern uncertainty. The new standard applies prospectively, to annual periods ending after December 15, 2016, and to annual and interim periods thereafter. Early adoption is permitted. The Company has evaluated the new standard and it is not expected to have an effect on its consolidated financial statements.

	Use of Estimates

	The preparation of consolidated financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in its financial statements. On an ongoing basis, the Company evaluates the estimates used in recording common stock warrant related liabilities, derivative financial instruments, stock-based compensation, and where applicable, the fair value of assets. The Company may base such estimates on various assumptions which it believes to be reasonable under the circumstances. Actual results could differ from those estimates.

	Cash and Cash Equivalents

	The Company considers all highly liquid securities with a maturity of three months or less at acquisition to be cash equivalents. Cash and cash equivalents include demand deposits with financial institutions and at times the amounts may exceed federally insured deposit limits. The Company has not experienced any losses and does not believe it is exposed to any significant credit risk related to demand deposits.

	Restricted Cash

	Restricted cash represents monies pledged by the Company’s foreign subsidiary for a lease obligation related to the manufacturing facility and to the Dutch government as required for companies with irradiator equipment.

	Concentrations of Credit Risk

	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash and cash equivalents with high-credit-quality financial institutions in the United States and the Netherlands.

	Cash and cash equivalents in the United States are maintained at financial institutions and, at times, balances may exceed federally insured limits. All non-interest bearing cash balances were fully insured to $250,000 per depositor at each financial institution, and noninterest bearing cash balances may again exceed federally insured limits.

	Cash and cash equivalents in The Netherlands are maintained at a financial institution and, at times, balances may exceed insured limits. Insurance coverage is limited to €100.000 for all Company accounts at each financial institution.

	The Company has not experienced any losses with respect to cash and cash equivalents.

	Inventory

	Inventory is reported at the lower of cost or market value. The Company analyzes its inventory and writes down inventory that has become obsolete, or has a cost basis in excess of its expected net realizable value and inventory quantities in excess of expected requirements. Inventory primarily consists of a product used in creating vaccines using the OncoVAX® technology platform to be utilized in the planned phase IIIb clinical trial and for research and development activities.

	The Company has determined that an obsolescence reserve is not required for the years ended December 31, 2014 and 2013.

	Property and Equipment

	Property and equipment are recorded at cost and are depreciated or amortized over their estimated useful lives using the straight-line method. Estimated useful lives are as follows:


	Machinery and equipment		3 – 5 years
	Automobile		3 – 5 years
	Furniture and fixtures		5 years
	Computers and software		3 years
	Leasehold improvements		Shorter of lease term or useful life

	Maintenance and repairs are charged to expense as incurred. Major betterments and improvements, which extend the useful life of the underlying assets, are capitalized and depreciated.

	Intangible Assets

	Intangible assets consist primarily of the cost of acquired patents associated with OncoVAX® to be used in research and development and the commercialization of cancer related vaccines. The Company has capitalized the cost of the acquired patents because the Company has identified alternative future research and development efforts for numerous forms of cancer which it intends to pursue and for which management believes will result in commercialization of related vaccines. Acquired patents are carried at cost less accumulated amortization. Amortization is calculated on a straight-line basis, over the estimated useful economic life of the patent, which is 12.6 years for OncoVAX®.

	Impairment of Long-Lived Assets

	The Company accounts for the impairment of long-lived assets in accordance with ASC No. 360, Property, Plant and Equipment, which requires that long-lived assets and certain identifiable intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No impairment losses have been recorded in the accompanying consolidated statements of operations.

	Foreign Currency Translation

	The financial statements of foreign subsidiaries are maintained in their functional currency, which generally is the local currency. The assets and liabilities are translated to U.S. dollars using the exchange rate in effect at the balance sheet date. Revenues, expenses and cash flows of these operations are translated using average exchange rates during the reporting period which they occur. The resulting translation adjustments are reflected in other comprehensive loss.

	Revenue Recognition

To date, the Company has not earned any revenues as the use of OncoVAX® to create cancer related vaccines still requires additional clinical trials and has not received regulatory approval for commercialization and sale.

Research and Development Expense

Research and development costs are expensed as incurred. Research and development expenses primarily include the amortization of intangible assets, cost of conducting clinical trials, compensation and related overhead for employees, consultants, facilities costs and the cost of materials purchased for research and development.

Stock-Based Compensation

The Company measures the cost of employee services received in exchange for stock options or restricted stock awards based upon the fair value of the award on the date of the grant. The Company recognizes the estimated grant date fair value of the award as stock-based compensation expense on a straight-line basis over the requisite service period, which is generally the vesting period.

The Company initially measures the cost of awards granted to non-employees based on the fair value of the award on the date of grant however such cost is re-measured at the end of each reporting period until performance is fully satisfied or services are rendered by the non-employee.

The fair value of stock options granted is calculated using the Black-Scholes option-pricing model, which requires the use of subjective assumptions including volatility, expected term, risk-free rate, and the fair value of the underlying common stock. The fair value of non-vested stock awards is determined based upon the estimated fair value of the Company's common stock.

Income Taxes

Deferred income tax assets and liabilities are determined based on differences between the financial statements and tax basis of assets and liabilities, as measured using the enacted tax rates, which are expected to be in effect when the differences reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. A full valuation allowance was recorded against its deferred tax assets for the years ended December 31, 2014 and 2013, respectively.

The tax effects of uncertain tax positions are recognized in the financial statements only if the position is more likely than not to be sustained on audit, based on the technical merits of the position. For tax positions meeting the more likely than not threshold, the amount recognized in the consolidated financial statements is the largest benefit that had greater than 50% likelihood of being realized. Management has not identified any uncertain tax positions with the exception of income tax return filing penalties and accordingly has established a liability of $100,000 and $130,000 under ASC 740-10 as of December 31, 2014 and 2013, respectively. It is the Company’s accounting policy to account for ASC 740-10 related penalties and interest by including those items in other liabilities/expenses and not in the income tax provision in the consolidated statements of operations. The Company has identified its U.S. Federal income tax return, its state return in Maryland and Netherlands corporate income tax returns as its major tax jurisdictions. Tax returns for fiscal years 2007 and forward are still open for examination.

Financial Instruments

Warrants Accounted for as Liabilities

Abell Warrants

In October 2011, the Company entered into a borrowing arrangement with The Abell Foundation (“Abell”). In connection with that arrangement, the Company also issued warrants (the “Abell Warrants”) exercisable into common stock of the Company. In February 2012, the Company and Abell amended the agreement to provide for additional borrowings (the “Abell Loan”). Between January 2013 and August 2014, the maturity of the Abell Loan was extended on various occasions and additional warrants were issued. The accounting treatment of these extensions is described within Note 7 to these consolidated financial statements.

In connection with the promissory note issued to The Abell Foundation, the Company granted The Abell Foundation a security interest in its patents related to OncoVAX®. The promissory note was paid in full on August 25, 2014 and Abell released its security interest in Vaccinogen’s patents.

The number of shares issuable pursuant to the Abell Warrants is based upon a fixed amount of $1.1 million divided by 85% of the per share price of stock sold in the next qualifying round of venture capital financing where the total proceeds are at least $35 million. The Abell Warrants have a contractual term of 10 years and were fully vested upon issuance.

As of December 31, 2014 and 2013, the estimated fair value of the Abell Warrants was $458,537 and $1,615,835, respectively. The Company recorded a gain of approximately $1.2 million and a loss of $784,030 for the years ended December 31, 2014 and 2013, respectively.

The Abell Warrants represent a fixed obligation that is to be settled through the issuance of a variable number of shares of the Company’s common stock. Consistent with the provisions of ASC Topic 480, Distinguishing Liabilities from Equity, the Company has concluded that the Abell Warrants should be accounted for as a liability. The Company is required to record the Abell Warrants at their estimated fair value at the end of each reporting period, with changes in the estimated fair value recorded in the consolidated statements of operations as a component of Loss on Financial Instruments.

Abell Investment Option

Accounting for Warrants – The Company has adopted FASB guidance related to determining whether an instrument or embedded feature is indexed to an entity’s own stock. This guidance applies to any freestanding financial instruments or embedded features that have the characteristics of a derivative, as defined in ASC Topic 815, Derivatives and hedging, and to any freestanding financial instruments that are potentially settled in an entity’s own common stock. As a result, certain warrants were considered to be derivatives and were valued using various assumptions as they are recorded as liabilities.

On January 16, 2013, the Company entered into an investment agreement with Abell under which Abell was granted an option to acquire up to $5.0 million of common stock of the Company (the “Abell Option”). On August 22, 2014 the Company entered into a letter agreement with Abell (the “Abell Amendment”), pursuant to which Abell agreed to either (a) purchase up to 909,091 shares of the Company’s common stock at $5.50 per share, for a total of up to $5,000,000, on or before the 14th day following Abell’s receipt of written notice (together with such further related information and documentation as Abell may reasonably require) that both (i) the first patient has been given three doses of OncoVAX, with positive results (Delayed-Type Hypersensitivity), in the next phase IIIb trial and (ii) the aggregate investment by TIS of at least $40,000,000 for the purchase of our securities in accordance with the TIS Agreement has occurred or (b) surrender its investment option if the conditions above have occurred and Abell chooses not to invest within such 14 day period. TIS executed the Abell Letter Agreement for the sole purpose of affirming our commitments to (x) relocate our offices to Baltimore, Maryland within 12 months of the closing of a financing of at least $35 million and (y) to construct and maintain our next and principal manufacturing facility in Baltimore, Maryland.

As of December 31, 2014 and 2013, the estimated fair value of the Abell Option was $0 and $7,392,528, which the Company has recorded a liability. The Company recorded a gain of $4,224,304 and a loss of $1,437,983 for the years ended December 31, 2014 and 2013, respectively.

The Abell Investment Agreement was determined to no longer be classified as a liability as of August 22, 2014, due to changes in terms and conditions of the instrument and was reclassified to permanent equity in the amount of approximately $3.2 million.

Derivative Financial Instruments

The Company may enter into transactions that represent free-standing or embedded derivative financial instruments as those terms are defined in ASC Topic 815 Derivatives and Hedging (“Topic 815”). The Company records the estimated fair value of derivative financial instruments in its consolidated balance sheets and records changes in the estimated fair value of derivative financial instruments as income or expense in its consolidated statements of operations.

Round C Warrants

From October 2012 through December 2013 and then again from January 2014 through December 31, 2014, the Company issued warrants to certain investors in the common stock of the Company (the “Round C Warrants”). Round C Warrants to acquire 339,966 shares of common stock were issued through December 2013 and Round C Warrants to acquire 990,281 shares of common stock were issued during the year ended December 31, 2014. The Round C Warrants have an exercise price of $6.05, a contractual term of 5 years and were fully vested upon issuance.

As of December 31, 2014 and 2013, the estimated fair value of the Round C Warrants was $1,359,647 and $1,796,427, respectively. The Company recorded a gain of $2,462,093 and a loss of $453,088 for the years ended December 31, 2014 and 2013, respectively.

2012 Bridge Loan

Between April 2012 and October 2012, the Company entered into transactions with various investors which resulted in the Company raising $1,019,000 from the issuance of unsecured notes payable (collectively the “Bridge Loan”). The Bridge Loan has no contractual maturity date, and is repayable only in the event that the Company closes on a future round of equity financing which results in gross proceeds of at least $20 million. If the Company fails to raise sufficient additional capital, there is no obligation to pay interest or repay any amount borrowed under the Bridge Loan. The Company did meet the $20 million threshold upon receipt of the second tranche of funding under the TIS Agreement and at that time the Company repaid an amount to the investors equal to 2 times the amount originally raised.

The Company has classified the Bridge Loan as a derivative financial instrument, as it met the qualifying criteria of ASC Topic 815 Derivatives and Hedging (“Topic 815”) including the contractual terms whereby the Company can be required to settle its obligation under the Bridge Loan by transferring cash to investors if and only when sufficient additional capital is raised. As of December 31, 2014 and 2013, the estimated fair value of the liability associated with the Bridge Loan was $0 and $990,000 respectively, which has been recorded and included in financial instruments in the accompanying consolidated balance sheets. The Company recorded a loss of $80,000 and $389,500 for the years ended December 31, 2014 and 2013, respectively.

The changes in the estimated fair value have been classified in Gain (Loss) on Financial Instruments in the accompanying consolidated statements of operations for the years ended December 31, 2014 and 2013.

Net Loss Per Share

Basic loss per share is determined by dividing the loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. The following common stock equivalents were excluded in the calculation of diluted loss per share because their effect would be anti-dilutive:

		2014		2013

Stock Option Pool			177,000		77,000
Abell Investment Option			909,091		934,579
Convertible debt			-		73,421
Restricted stock awards			179,969		129,846
Warrants			4,759,065		3,310,378

Dilutive loss per share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. The net loss available to common shareholders is adjusted for gains on financial instruments, as its effect would be anti-dilutive.

		Year ended December 31, 2014
				Weighted		Loss
				Average		Per
		Net Loss		Shares		Share

Basic loss per share		$	-8,526,805		32,760,479	$	-0.26
Gain on derivatives			-7,753,694

Dilutive loss per share		$	-16,280,499		32,760,479	$	-0.5

		Year ended December 31, 2013
				Weighted		Loss
				Average		Per
		Net Loss		Shares		Share

Basic loss per share		$	-24,580,541		31,089,148	$	-0.79
Gain on derivatives			0

Dilutive loss per share		$	-24,580,541		31,089,148	$	-0.79

Agreements_with_Intracel

Agreements with Intracel	12 Months Ended
Agreements with Intracel	Dec. 31, 2014
Agreement [Abstract]
Agreement [Text Block]	4. Agreements with Intracel

	License Agreement

	On October 10, 2007, the Company entered into an agreement (the “License Agreement”) with Intracel Holdings Corporation (“Intracel”), for the exclusive and indefinite rights to license and use the OncoVAX® technology platform. OncoVAX® is an active specific immunotherapy (“ASI”) that uses the patient’s own cancer cells to block the return of cancer following surgery. In exchange for the rights to OncoVAX®, the Company (i) agreed to issue equity securities equal to 10% of the fully diluted capitalization of the Company, (ii) assumed liabilities of Intracel to Organon Teknika Corporation (“Organon”) totaling $4.0 million under an October 31, 2007 Letter Agreement between Intracel and Organon, (iii) agreed to pay $450,000 in cash for settling trade payable related to the OncoVAX intellectual property, and (iv) agreed to make royalty payments to Intracel based on future sales of OncoVAX®. The terms of the securities issued to Intracel provided Intracel with anti-dilution rights with respect to its 10% ownership interest. The License Agreement also contained a provision such that if the Company obtained specified levels of financing in a specified time period, that title to OncoVAX® would transfer to the Company without further consideration. If the Company did not reach the specified levels of financing in the specified period of time, Intracel could cancel the License Agreement and could re-purchase the rights to OncoVAX®. The Company did not obtain the necessary financing in the period specified.

	In connection with the License Agreement, the Company issued 1,506,750 shares of common stock valued at approximately $984,000 and assumed liabilities with an estimated value of $4,450,000. The Company estimated the fair value of the liabilities assumed based upon their face amount as these liabilities were due currently and on demand.

	On August 22, 2014 Intracel and Vaccinogen entered into an Agreement, whereby the License Agreement will terminate and no longer be of any force or effect once TIS invests in Vaccinogen the aggregate amount of $80,000,000. Vaccinogen shall no longer, from that point, have any obligation to pay to Intracel any royalties or other payments under the Original License Agreement and/or the License Amendment.

	Asset Transfer Agreement and Stock Exchange Agreement

	As a result of the Company’s inability to raise the necessary capital under the License Agreement, the Company and Intracel negotiated amended terms to the License Agreement. On June 24, 2010, the Company and Intracel entered into the Asset Transfer Agreement pursuant to which the title to all of the intellectual property associated with OncoVAX® was transferred to the Company. Under the Asset Transfer Agreement, the Company also agreed to exchange the previously issued common stock and Series AA preferred stock representing a 10% interest in the Company for shares of its Series B preferred stock equal to a 20% interest in the Company on a fully diluted basis.

	The terms and conditions of the Series B preferred stock provided Intracel with anti-dilution rights with respect to its 20% ownership interest. In addition, the Company agreed that Intracel’s ownership position (and corresponding anti-dilution rights) would increase to 50% upon failure of the Company to meet certain defined milestones, which included but were not limited to, the Company attaining specified levels of additional financing.

	The Company accounted for the acquisition of the rights to the OncoVAX® technology platform under the License Agreement in 2007 and the Asset Transfer Agreement in 2010 as an asset acquisition in accordance with ASC Topic 805, Business Combinations. Furthermore, as described in Note 1 to these consolidated financial statements, and in accordance with ASC Topic 730, Research and Development, the Company has capitalized the cost of acquiring the rights to OncoVAX® technology platform as these rights represent intangible assets to be used in research and development activities and for which future alternative uses exist.

	In June 2010, in connection with the Asset Transfer Agreement, the Company issued 3,452,766 shares of Series B preferred stock, with an estimated value of approximately $16.8 million. The Company estimated the fair value of the common stock issued pursuant to the License Agreement and the Series B Preferred Stock issued pursuant to the Asset Transfer Agreement by considering various commonly accepted valuation techniques, including the income and market approaches.

	The Company ultimately relied on the income approach, specifically, the discounted cash flow method, to estimate the value of the Company’s equity. The Company further utilized commonly used option pricing techniques to estimate the fair value of the various equity classes. The use of the income approach, and specifically the discounted cash flow method, requires management to make significant assumptions about the future level and timing of revenues, direct and indirect costs associated with continued research and development, the conduct of clinical trials, and the production and commercialization of the intended cancer vaccines. The discounted cash flow method also requires the estimation of discount rates used to reflect the risk inherent in the projected cash flows, the terminal growth rate, among other factors.

	The Company did not meet these milestones and consequently, in December 2010, was required to increase Intracel’s total ownership interest in the Company to 50% through the issuance of additional shares of Series B preferred stock.

	In December 2010, the Company issued 10,973,612 additional shares of Series B preferred stock to Intracel when the Company failed to meet certain conditions of the Asset Transfer Agreement. The estimated value of those additional shares of approximately $63.1 million was accounted for as additional consideration and is included in the total cost of acquiring the OncoVAX® technology platform.

	All shares of Series B preferred stock were converted to common stock in 2012.

	As of April 10, 2015 Intracel directly owns approximately 37% of the Company on a fully diluted basis, and all directors and executive officers of Vaccinogen collectively own approximately 37% of the Company on a fully diluted basis.

Property_and_Equipment

Property and Equipment	12 Months Ended
Property and Equipment	Dec. 31, 2014
Property, Plant and Equipment, Net [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	5. Property and Equipment

	Property and equipment consisted of the following:

	December 31,	2014		2013

	Machinery and equipment	$	740,042	$	903,964
	Leasehold improvements		258,505		-
	Furniture and fixtures		31,764		35,690
	Computers and software		119,473		1,929
			1,149,784		941,583

	Less accumulated depreciation	$	-756,738	$	-742,793

		$	393,046	$	198,790

	Depreciation expense was $51,837 and $24,165 for the years ended December 31, 2014 and 2013, respectively.

Intangible_Assets

Intangible Assets	12 Months Ended
Intangible Assets	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Intangible Assets Disclosure [Text Block]	6. Intangible Assets

	Intangible assets consist of the capitalized costs associated with the acquisition of patents related to OncoVAX® (the “Intellectual Property”) and the costs associated with website development and domain names.

	Intangible assets by major asset class were as follows at December 31, 2014:

		Gross Carrying		Accumulated		Net Carrying
		Amount		Amortization		Amount

	Intellectual Property	$	84,481,856		-28,490,967	$	55,990,889
	Other Intangible Assets		121,944		-90,544	$	31,400

		$	84,603,800		-28,581,511	$	56,022,289

	Intangible assets by major asset class were as follows at December 31, 2013:

		Gross Carrying		Accumulated		Net Carrying
		Amount		Amortization		Amount

	Intellectual Property	$	84,481,856		-21,792,439	$	62,689,417
	Other Intangible Assets		121,944		-85,802		36,142

		$	84,603,800		-21,878,241	$	62,725,559

	The amortization expense for intangible assets was approximately $6.7 million for the years ended December 31, 2014 and 2013. The weighted average amortization period for intangible assets was 12.6 years.

	The estimated future amortization relating to all intangible assets that are recorded in the consolidated balance sheets as of December 31, 2014 is as follows:

	Years ending December 31,

	2015	$	6,702,516
	2016		6,702,516
	2017		6,702,516
	2018		6,702,516
	2019		6,702,516
	Thereafter		22,509,709

		$	56,022,289

Prepaid_Expenses_and_Other_Cur

Prepaid Expenses and Other Current Assets	12 Months Ended
Prepaid Expenses and Other Current Assets	Dec. 31, 2014
Prepaid Expense and Other Assets, Current [Abstract]
Prepaid Expense And Other Assets Current [Text Block]	7. Prepaid Expenses and Other Current Assets

	Prepaid expenses and other current assets consisted of the following:

	December 31,	2014		2013

	Prepaid Clinical Trial expense	$	2,477,571	$	-
	Prepaid Other		432,905		115,522
		$	2,910,476	$	115,522

	The prepaid balance for 2014 consists primarily of payments made under the Company’s contract with RXTRIALS, Inc. d/b/a OnPoint CRO of approximately $2.4 million.

Notes_Payable

Notes Payable	12 Months Ended
	Dec. 31, 2014
Notes Payable [Abstract]
Short-term Debt [Text Block]	8. Notes Payable

	December 31,	2014		2013

	Organon Obligation	$	3,000,000	$	3,500,000
	Abell Loan		-		1,331,217

		$	3,000,000	$	4,831,217

	Organon Obligation

	Organon, currently owned by Merck & Co, Inc., manufactures a key component used with the OncoVAX® technology. In 2007, in conjunction with the Agreement with Intracel, the Company assumed $4.0 million of related liabilities from Intracel due to Organon (“Organon Obligation”). Of the $4.0 million due to Organon, $500,000 was paid at the time of the Agreement. The remaining $3.5 million was due in installments with an additional $500,000 (plus accrued interest) payable the first year but no later than one year after the agreement date of October 31, 2007. Organon may elect to receive this first $500,000 installment in stock. Commencing one year after the earlier of the first marketing approval of OncoVAX® by the United States Food and Drug Administration or the European Medicines Agency or October 31, 2007, Vaccinogen would make an annual payment of $1.0 million to Organon until repayment of the entire liability amount. The obligation accrued interest based on a simple annual interest rate based on the US prime lending rate in effect on the anniversary date of the agreement, or October 31, 2008, which was 4.00%. Interest expense under this agreement was approximately $136,666 and $96,314 for the year ended December 31, 2014 and 2013, respectively. The accrued interest on this obligation is shown on the consolidated Balance Sheet as accrued interest.This obligation was secured by the OncoVAX® Intellectual Property.

	While the Company did not pay the installment due one year after the Agreement, no event of default has been declared by Organon or its successors including Merck & Co, Inc. and the statute of limitations expired on November 1, 2014. As of that date, the $500,000 installment due was included in Other Income and the related accrued interest of $140,000 was recorded as a reduction in interest expense. Since payments are not subject to future events which will not occur within the next twelve months, the remaining principal and accrued interest has been classified as a long term liability in the accompanying consolidated balance sheets.

	Abell Loan

	On October 26, 2011, the Company obtained a $1.5 million working capital loan from The Abell Foundation Inc. (“Abell”). The Abell Loan was originally due on April 26, 2012, with 8% simple interest accruing and payable on the maturity date. On February 16, 2012, the Company received an additional $300,000, thereby increasing the amount outstanding to $1.8 million.

	The Abell Loan was repaid in full on August 25, 2014.

	Debt, Modifications and Extinguishments

	The Abell Loan underwent several amendments which were treated either as debt modifications or debt extinguishments, with the most recent being the extension of the maturity date of the loan to August 26, 2014. No costs or expenses were incurred by the Company in connection with the August 2014 extension.

	The July 2013 amendment required the issuance of a fixed number of shares at various points in time known as Contingent Share Warrants. The Contingent Share Warrants are not considered a derivative instrument as they are considered indexed to the Company’s own stock as defined by ASC 815-40. As a result, the value assigned to the Contingent Share Warrants has been classified within stockholders’ equity. The outstanding debt was not repaid in full December 31, 2013 and 300,000 warrants were issued to Abell. The warrants were valued using the Black-Scholes method, and for the year ending December 31, 2014 approximately $0.4 million was included in interest expense.

	Contingent Share Warrants were issued and valued using the Black-Scholes method, and for the years ended December 31, 2014 and 2013, $1,818,642 and $1,751,108 was included in interest expense and other expenses, respectively.

	The Company recorded interest expense related to the Abell Loan of approximately $48,000 and $133,000 for the years ended December 31, 2014 and 2013, respectively.

Fair_Value_Measurements

Fair Value Measurements	12 Months Ended
Fair Value Measurements	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	9. Fair Value Measurements

	Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction occurring in the most advantageous market. The Company determines fair value based on a hierarchy that priorities valuation techniques used to measure fair value based on observable and unobservable inputs. Observable inputs reflect market data obtained from independent sources. Unobservable inputs reflect assumptions based on the best information available.

	The three levels of the fair value hierarchy are:

	Level 1 — Inputs are quoted prices for identical assets or liabilities in an active market

	Level 2 — Inputs include quoted prices in active markets for similar assets and liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (interest rates and yield curves), and inputs that are derived principally from or corroborated by observable market data correlation or other means

	Level 3 — Inputs that are unobservable and significant to the fair value measurement

	The Company is required to record or disclose the fair value of certain assets and liabilities. The fair value guidance described above is used in measuring and recording the fair value of the liability associated with the Abell Warrants, and the fair value of the financial derivatives including the Round C Warrants and the Bridge Financing. This fair value guidance also applies to the disclosure of the fair value of financial instruments not otherwise recorded in the Company’s consolidated balance sheet at fair value.

	The Company’s financial instruments measured on a recurring basis using fair value estimates are as follows:

					December 31, 2014
	Description		Total		Level 1			Level 2			Level 3

	Abell Warrants		$	438,537	$	-		$	-		$	438,537
	Round C Warrants			1,359,647		-			-			1,359,647

			$	1,798,184	$	-		$	-		$	1,798,184

					December 31, 2013
	Description		Total		Level 1			Level 2			Level 3

	Abell Warrants		$	1,615,835	$	-		$	-		$	1,615,835
	Round C Warrants			1,796,427		-			-			1,796,427
	Bridge Loan			990,000		-			-			990,000
	Abell Investment Option			7,392,528		-			-			7,392,528

			$	11,794,790	$	-		$	-		$	11,794,790

	The following is a reconciliation of the fair value measurements from January 1, 2013 to December 31, 2014.

			Abell		Round C			Bridge			Abell
			Warrants		Warrants			Loan			Option

	Balance, January 1, 2013		$	831,806	$	230,349		$	1,528,500		$	-
	Issuance of securities			275,813		1,112,990			-938,000			5,954,545
	Fair value change included in earnings			508,216		453,088			399,500			1,437,983

	Balance, December 31, 2013			1,615,835		1,796,427			990,000			7,392,528
	Issuance of securities			37,529		2,025,313			-			-
	Repayment/extinguishment of debt			-		-			-1,100,000			-3,168,224
	Fair value change included in earnings			-1,214,827		-2,462,093			110,000			-4,224,304

	Balance, December 31, 2014		$	438,537	$	1,359,647		$	-		$	-

	Quantitative Information

	Quantitative information as of December 31, 2014 with respect to financial instruments measured and carried at fair value on a recurring basis with the use of significant unobservable inputs (Level 3) are as follows:

	Level 3 - Significant Unobservable Inputs
	Description		Fair Value		Principal Valuation		Unobservable		Range
					Techniques		Inputs		(Weighted
									Average)

	Abell Warrants		$	438,537	Black-Scholes		Strike price Equity volatility		N/A
	Round C Warrants		$	1,359,647	Black-Scholes		Strike price Equity volatility		N/A

	Abell Warrants and Round C Warrants

The fair value of the Abell Warrants and the Round C Warrants are estimated at the end of each reporting period using an option pricing model. More specifically, the Black-Scholes option pricing model was utilized in the valuation of both the Abell Warrants and the Round C Warrants. The following assumptions were used:

		Abell Warrants							Round C Warrants
		2014			2013				2014				2013

Volatility			94	%		80	%			87	%			80	%
Exercise price		$	4.55		$	4.68			$	5.88			$	5.88
Stock price at December 31		$	2.2		$	7.91			$	2.2			$	7.91
Risk free interest rate			2.17	%		3.04	%			1.02% - 1.65	%			1.13% - 1.75	%
Dividend yield			0	%		0	%			0	%			0	%
Expected life			10			10				2.8 -5.0				3.7 -5.0

The exercise price of the Abell Warrants is ultimately dependent upon the per share price and size of future rounds of equity financing. The Black-Scholes option pricing model was used to value the Abell Warrants as management believes that it can reasonably estimate the terms and conditions of future equity offerings that would impact the valuation of the Abell Warrants. Management’s ability to estimate these terms is based in part upon the terms and conditions of binding agreements to raise future equity capital in place at the time of each valuation.

The Round C Warrants include a form of anti-dilution protection that may result in future adjustments to the terms of the warrants.

The fair value calculations include the use of both observable and estimated inputs. There remains an inherent subjectivity in the development of the strike price used for both the Abell and Round C Warrants. Therefore, the Company considers the derived fair value to have been determined using Level 3 inputs.

Significant changes to the assumptions used in the Company’s model would result in changes in the fair value of the Abell Warrants and the Round C Warrants.

Abell Option

Management has valued the Abell Option based upon an estimate of the fair value of the Company’s underlying stock because management believes it can reasonably estimate the occurrence and the terms of the future equity offering necessary to trigger Abell’s right to exercise the option.

As of January 16, 2013, the date of issuance for the Abell Option, the Company reasonably expected the undiscounted common stock price issuable to be $5.50 per share, discounted to $4.40 per share. Therefore, the $5 million investment divided by the discounted share price of $4.40 yielded an option for 1,136,364 shares. At December 31, 2014, the estimated number of shares is 934,580 in recognition of the expected Venture Capital Financing price per share of $5.35, the effective price of the Round C issuances.

In August 2014, the Abell Investment Option was modified, including changes to the terms of the optional investment (now a fixed number of shares (909,091) and a fixed purchase price ($5.50 per share), certain defined operating conditions, and a set expiry period; whereas the original investment terms were $5 million worth of common stock valued at the lowest sales price in effect at the time, and no expiry period (i.e., perpetual option).

Historically, the Company had determined that the Investment Option was a liability pursuant to the guidance contained in ASC 480, and as such should be marked to its fair value at each balance sheet date since they were determined to be probable of occurrence. Since the modification eliminated the variability in the Investment Option (the number of shares and purchase price are now fixed), in effect the Investment Agreement is now similar to a contingent “written call” or warrant where the investor can buy a fixed number of shares at a fixed price; as such the Investment Option is no longer within the scope of ASC 480.

The Company accounted the new terms of the Abell option under EITF 00-19 (ASC 815-40-25-1 through 25-43 and related interpretative guidance in ASC 815-40-55-1 through 55-18). Since the written call are fixed (fixed number of shares at a fixed price), it is considered indexed to the Company’s own stock and treated as an equity instrument and should be classified under stockholders’ equity. The value of the Abell option as of the effective date, August 22, 2014, was $3,168,224. The Company removed this amount from financial liabilities and included the same to additional paid-in capital under the stockholder’s equity section in the unaudited condensed consolidated balance sheets.

Bridge Loan

The estimated fair value of the Bridge Loan was determined based upon the present value of probability weighted cash flows, using assumptions about the timing and amount of future cash flows and discount rates that management considers to be appropriate in the circumstances.

Because of the inherent subjectivity in management’s assumptions, the Company considers the derived fair value to have been determined using Level 3 inputs.

Disclosure of the Fair Value of Financial Instruments

Cash and cash equivalents and accounts payable, are carried at amounts that approximate their fair values due to the short term nature of these financial instruments. The fair value of the Abell Loan approximates its carrying value due to the short term nature of the Abell Loan’s maturity. The fair value of the Organon Obligation approximates its carrying value as the note is due on demand.

Stockholders_Equity

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Dec. 31, 2014
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	10. Stockholders’ Equity

	In August 2012, the Company amended and restated its Certificate of Incorporation to increase the number of shares authorized for issuance to 200,000,000 shares of common stock with a par value $.0001 and 50,000,000 shares of preferred stock with a par value of $.0001 per share.

	During 2014, the Company raised additional capital of $17,830,303 through the issuance of 3,246,417 shares of common stock (Round C), 90,923 adjustment shares and common stock warrants (Round C Warrants) to purchase 972,525 shares of common stock. $15,200,689 was allocated to the common stock; $1,947,224 was allocated to the common stock warrants; and $682,390 represents placement agent commissions paid. The Round C common stock warrants were determined to be a derivative financial instrument.

	In addition, during 2014, an investor in the Bridge Loan opted to convert its loan to equity in the amount of $300,000 and the Company issued 54,545 shares of common stock (Round C), 1,530 adjustment shares and common stock warrants (Round C Warrants) exercisable into 16,363 shares of common stock. $227,939 was allocated to the common stock and $72,061 was allocated to the common stock warrants. Also in 2014, a payable in the amount of $25,000 was converted into 4,545 shares of the Company’s common stock (Round C), 128 adjustment shares and common stock warrants (Round C Warrants) to purchase 1,363 shares of common stock $18,966 was allocated to common stock and $6,034 was allocated to the common stock warrants. The common stock warrants were determined to be a derivative financial instrument. The terms and conditions of the Round C Warrants are described in Note 3 to the consolidated financial statements.

	During 2013, the Company raised additional capital of $4,205,105 through the issuance of 764,578 shares of common stock (Round C), 21,465 adjustment shares and common stock warrants (Round C Warrants) to purchase 229,368 shares of common stock. $3,253,316 was allocated to the common stock; $926,581 was allocated to the common stock warrants; and $25,288 represents placement agent commissions paid. The Round C common stock warrants were determined to be a derivative financial instrument.

	In addition, during 2013, several investors in the Bridge Loan opted to convert their loan to equity in the amount of $937,970 and the Company issued 170,540 shares of common stock (Round C), 4.787 adjustment shares and common stock warrants (Round C Warrants) exercisable into 51,159 shares of common stock. $751,561 was allocated to the common stock and $186,409 was allocated to the common stock warrants. The common stock warrants were determined to be a derivative financial instrument. The terms and conditions of the Round C Warrants are described in Note 3 to the consolidated financial statements.

	Round C Common Stock

	The subscription agreement for the Company’s most recent financing, beginning October 2012, through the issuance of common stock (“Round C”) provides a form of anti-dilution protection to subscribers. The anti-dilution rights are determined to be clearly and closely related to the Round C common stock as that term is defined in Topic 815 and as a result these rights are not required to be accounted for as a free standing derivative financial instrument.

	The Company filed a Form S-1 Registration Statement with the SEC, which became effective on October 31, 2013. The market price of Vaccinogen stock as of that date was $5.35. Pursuant to the protection provided to subscribers prior to October 31, 2013, 27,213 adjustment shares were issued. All subscriptions subsequent to the October 31, 2013 effective date through December 31, 2013 have been issued adjustment shares, totaling 92,581 adjustment shares, for the year ended December 31, 2014. All of the adjustment shares are included in the calculation of total shares issued or outstanding for the years ended December 31, 2014 and 2013.

	The Company has increased the size of the Round C Private Placement Offering to $30,800,000 (5,600,000 Units) and has approved a Final Closing Date to January 31, 2015.

StockBased_Compensation

Stock-Based Compensation	12 Months Ended
Stock-Based Compensation	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	11. Stock-Based Compensation

	Restricted Stock

	The Company from time to time has authorized shares of restricted common shares as director compensation. From August 2010 through December 31, 2014, the Company authorized 179,969 shares of restricted common stock to directors whose vesting will be determined by the approval of a 2015 Stock Incentive Plan.

	The Company records compensation expense for the award of restricted stock based upon the awards fair value determined as the difference in the estimated fair value of the Company’s common stock and the price paid by the employee, if any, generally on the date of grant. The fair value of restricted stock awards is recognized as compensation expense over the service period which is generally the same as the vesting period. No compensation cost has been or will be recognized for the restricted stock awards whose vesting is contingent upon a approval of a 2015 Stock Incentive Plan. No compensation expense related to awards with service based vesting was recorded for the years ended December 31, 2014 and 2013.

	The following table summarizes activity related to restricted-stock awards for 2014 and 2013. The weighted average fair values for the awards below are based on the fair value at the grant date of the respective awards, which is equal to the value of the Company’s common stock on such date.

			2014						2013
						Weighted					Weighted
						Average Fair					Average Fair
			Shares			Value			Shares		Value

	Balance, beginning of year			129,846		$	3.77			119,734	$	3.42
	Granted			50,123		$	2.2			10,112	$	7.91
	Vested			-		$	-			-	$	-
	Forfeitures			-		$	-			-	$	-

	Balance, end of year			179,969		$	3.35			129,846	$	3.77

	As of December 31, 2014 and 2013, total unrecognized compensation costs related to nonvested restricted stock awards to purchase 179,969 and 134,278 shares of common stock was approximately $604,000 and $489,000 respectively, which will be recognized upon the approval and implementation of the 2015 Stock Incentive Plan. No awards vested during the years ended December 31, 2014 and 2013.

	Stock Option Pool

	The Company recorded stock based compensation in the amount of $86,943 and $46,543 for the years ended December 31, 2014 and 2013, respectively. For the years ended December 31, 2014 and 2013, $27,019 and $10,777 was allocated to General & Administrative expense with $59,924 and $35,766 was allocated to Research & Development, respectively.

	Total compensation costs for unvested stock option awards outstanding at December 31, 2014 was approximately $375,000 to be recognized over approximately 3.0 years.

	The Company uses the Black-Scholes option pricing model to calculate the fair value of options. The significant assumptions for options issued in 2014, used in this model include:

	Annual Dividend	-
	Expected life (in years)	6.25 – 10.00
	Risk free interest rate	1.35% - 2.17%
	Expected volatility	80%

	The following table summarizes the Stock Option pool activity for 2014.

						Weighted			Weighted
						Average			Average
			Shares			Exercise			Remaining
			Shares			Price			Life

	Balance, beginning of year			77,000		$	7			-
	Granted			100,000		$	3.64			-
	Forfeited			-		$	-			-
	Balance, end of year			177,000		$	6.44			8.72

	Stock Purchase Warrants

	From time to time the Company has issued stock purchase warrants to non-employees in exchange for services. As of December 31, 2014 and 2013 there are 820,575 and 785,575, respectively, warrants issued and outstanding with exercise prices ranging from $1.00 to $7.50. To date, all warrants have been issued with the exercise price at least equal to the then estimated fair value of the underlying security, and had contractual terms ranging from 2.5 to 7.5 years.

	The following table summarizes the stock purchase warrant activity for 2014 and 2013.

			2014						2013
			Shares			Weighted			Shares		Weighted
						Average Fair					Average Fair
						Value					Value

	Balance, beginning of year			785,575		$	1.48			785,575	$	1.48
	Granted			35,000		$	4.22			-	$	-

	Balance, end of year			820,575		$	1.6			785,575	$	1.48

The following table summarizes information on stock purchase warrants outstanding as of December 31, 2014:

Exercise price			Shares			Weighted			Weighted
						Average			Average
						Remaining			Exercise
						Life			Price

$	1			705,575			1.05		$	1
$	5.5			80,000			3.74		$	5.5
$	7.5			35,000			4.34		$	7.5

	Total			820,575			2.35		$	1.72

Common Stock Warrants

The following table summarizes the warrant activity for 2013 and 2014 and is inclusive of the Abell Warrants, the Round C Warrants, the Stock Purchase Warrants and represents the total outstanding warrants.

		Shares			Weighted			Weighted
					Average			Average
					Exercise Price			Remaining Life
Outstanding at January 1, 2013			2,663,648		$	1.48			1.81
Granted			646,730		$	5.2			7.66
Exercised			-		$	-			-
Expired			-		$	-			-
Outstanding at December 31, 2013			3,310,378		$	2.2			2.95
Granted			1,448,687		$	5.69			5.91
Exercised			-		$	-			-
Expired			-		$	-			-
Outstanding at December 31, 2014			4,759,065		$	1.73			3.77

The warrants granted in the years ended December 31, 2014 and 2013 had a weighted average fair value at grant date of $4.25 and $4.76 respectively.

The following table summarizes the outstanding warrants by year of expiration:

		Shares
2015			1,151,690
2016			1,201,475
2017			59,439
2018			360,527
2019			765,861
Thereafter			1,220,073
Total			4,759,065

Commitments_and_Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	12. Commitments and Contingencies

	Leases

	The Company leases office space, a manufacturing facility, and equipment under operating leases expiring in 2018. In addition, the Company leases storage facilities on a month to month basis. Rent expense was approximately $162,000 and $160,000 for the years ended December 31, 2014 and 2013, respectively.

	Minimum future lease payments under non-cancelable operating leases, at December 31, 2014 were as follows:

	For year ended December 31,	Amount
	2015	$	210,887
	2016		210,170
	2017		214,297
	2018		89,950
	Total	$	725,304

	Royalty Agreement with Intracel

	Pursuant to the Agreement (see Note 7), the Company agreed to pay Intracel the following royalties on the Net Sales of Royalty Bearing Products (as defined): (i) 3% of net sales on the first $350.0 million of Net Sales of Colon Cancer Products occurring in the calendar year; (ii) 4% of net sales of Net Sales of Royalty Bearing Products occurring in the calendar year in excess of $350.0 million and up to and including $750.0 million and (iii) 5% of net sales of Net Sales of Royalty Bearing Products occurring in the calendar year in excess of $750.0 million.

	On August 22, 2014 Intracel and Vaccinogen entered into an Agreement, whereby the License Agreement will terminate and no longer be of any force or effect once TIS invests in Vaccinogen the aggregate amount of $80,000,000. Vaccinogen shall no longer, from that point, have any obligation to pay to Intracel any royalties or other payments under the original License Agreement and/or License Amendment.

	Royalty Agreement with Organon

	The Company has agreed to pay Organon a royalty of 10% of the Net Sales of OncoVAX® (and all other TICE BCG related products, if any) until the Organon Obligation is paid in full, including interest, and 3% for 5 years thereafter.

	Litigation

	The Company may be subject to certain claims arising in the ordinary course of business. The Company and a vendor were in dispute over amounts owed for services performed. A demand for payment under a written agreement was made against the Company in the amount of approximately $150,000 and was settled for $65,000 in November 2014.

	VAT Taxes

	The foreign subsidiary of the Company, located in The Netherlands, was presented with a VAT tax bill for the years 2010 and 2011 in the amount of €65,666. The Company is appealing the decision as we believe that we should be VAT exempt. There has not yet been a decision made by the Dutch authorities and there is no estimate of when a decision will be made. In the event an unfavorable decision is made, the Company will be required to pay the full amount plus interest. The original bill at the December 31, 2014 exchange rate would have a USD equivalent of approximately $79,800. There has been no expense accrued on the accompanying consolidated financial statements.

Related_Party_Transactions

Related Party Transactions	12 Months Ended
	Dec. 31, 2014
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]		13	Related Party Transactions

	During April 2014, an executive of the Company loaned the Company $20,000. As of December 31, 2014, the loan was fully paid.

	In 2012, an executive of the Company loaned the Company $10,000. As of December 31, 2013, the balance due of $4,099 is past due and in default. The carrying value of this amount due to the Company executive is included in related party payable in the accompanying consolidated balance sheets as of December 31, 2013. As of December 31, 2014, the loan was fully paid.

	In December 2013, an executive of the Company loaned the Company $50,000. As of December 31, 2013, the balance due of $20,000 is past due. The carrying value of this amount due to the Company executive is included in related party payable in the accompanying consolidated balance sheets as of December 31, 2013. As of December 31, 2014, the loan was fully paid.

Income_Taxes

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	14. Income Taxes

	The Company is subject to U.S. Federal, state and foreign income taxes. The provision/(benefit) for income taxes for the tax years ended December 31, 2014 and 2013 are as follows:

			December 31,
			2014				2013

	Current:
	Federal		$	206,568			$	-
	State			31,649				-
	Foreign			-				-

	Total Current			238,217				-

	Deferred:
	Federal			(3,932,476	)			(4,466,979	)
	State			(629,774	)			(715,374	)
	Foreign			(223,923	)			(165,845	)

	Total Deferred (Provision)/Benefit			(4,786,173	)			(5,348,198	)
	Valuation Allowance			4,786,173				5,348,198

	Total Tax Provision/(Benefit)		$	238,217			$	-

	The Company has approximately $10.1 million of net operating loss (“NOL”) available for foreign purposes as of December 31, 2014, which will expire between 2016 and 2023.

	A reconciliation of the U.S. federal statutory income tax rate to the Company’s consolidated effective income tax rate for the years ended December 31, 2014 and 2013 is as follows:

	Effective Rate Reconciliation
	Years ended		12/31/14				12/31/13

	Income tax at statutory rate		34%				34%
	Financial instruments		32%				-12%
	State taxes - (net of fed)		5%				3%
	International rate difference		-10%				-1%
	Amortization of prepaid		-3%				0%
	Change-valuation allowance - fed		-64%				-22%
	All other items		3%				-2%
	Effective income tax rate		-3%				0%

	The temporary differences that arise between financial statement reporting and income tax basis carrying amounts of assets and liabilities give rise to deferred income taxes. The Company’s deferred income tax assets and liabilities as of December 31, 2014 and 2013 were as follows:

	Start-up expenditures and amortization			8,036,569				5,910,419
	Amortization of intangibles			4,996,993				8,631,105
	Financial instruments			1,408,087				705,008
	Nonqualified stock options			478,061				343,372
	U.S. net operating loss			-				2,576,756
	Foreign net operating loss			2,020,627				1,796,704
	Total long-term deferred income taxes:			16,940,337				19,963,364
	Valuation allowance			(16,940,337	)			(19,963,364	)
	Total Current and Deferred Income Tax Assets/(Liabilities)		$	-			$	-

	Total long-term deferred income tax assets represent $2.0 and $1.8 million related to non-U.S. operations for years December 31, 2014 and December 31, 2013, respectively. A valuation allowance is maintained against all amounts.

	Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to utilize the existing deferred tax assets. A significant piece of the objective negative evidence evaluated was the cumulative loss incurred over the three year period ended December 31, 2014. Such objective evidence limits the ability to consider other subjective evidence such as our projection for future growth.

	On the basis of this evaluation, as of December 31, 2014 and 2013, a valuation allowance of $16.9 million and $20.0 million has been recorded to record the portion of the deferred tax asset that is more likely than not to be realized. The amount of the deferred tax asset considered realizable, however, could be adjusted if estimates of future taxable income during the carryforward period are reduced or increased or if objective negative evidence in the form of cumulative losses is no longer present and additional weight may be given to subjective evidence such as our projections for growth.

	The Company is subject to income taxes in the U.S. as well as certain state and foreign jurisdictions. Tax regulations within each jurisdiction are subject to interpretation and require significant judgment to apply.

	U.S. federal income taxes have not been provided on undistributed earnings of our international subsidiaries as it is our intention to reinvest these earnings into respective subsidiaries. At December 31, 2014 the Company has not provided for U.S. federal income and non-U.S. withholding taxes as the international subsidiaries do not have undistributed earnings, only deficits to date.

	As of December 31, 2014 and 2013 there were $8,914,027 and $130,000 of unrecognized tax benefits that if recognized would be recorded as a component of continuing operations. The remaining unrecognized benefits represent federal and state taxes on intercompany transactions between the Company and its international subsidiaries.

		2014				2013
Unrecognized tax benefits, beginning of the year		$	130,000			$	90,000
Decreases for tax positions related to prior years			(30,000	)			-
Increases for tax positions taken during the year			8,814,027				40,000
Unrecognized tax benefits, end of the year		$	8,914,027			$	130,000

As a result of an intercompany sale of intellectual property during 2014, for ASC 740-10 purposes, the Company recorded an unrecognized tax benefit of $8.8 million. Under ASC 810-10-45-1 (formerly known as “ARB 51”), the GAAP and tax gains were eliminated in consolidation. ASC 810-10-45 guidance provides for a prepaid tax asset to be recorded for the same amount as the unrecognized tax benefit. The prepaid tax asset is being amortized as tax expense over the life of the intellectual property. The ASC 740-10 reserve recorded for this transaction will reverse in the future as the gain is reported on the Company’s US tax returns. Income tax expense represents the amortization of the Prepaid Income Tax for the period of October 1, 2014 through December 31, 2014.

It is the Company’s accounting policy to account for ASC 740-10 related penalties and interest in other liabilities/expenses and not to include them within he income tax expense line in the consolidated statement of operations.

As of December 31, 2014 the statutes of limitation, for U.S. purposes, are open for the 2007 through 2013 tax years and we are not expected to close within the next twelve months. The Company is not currently under examination by the taxing authority.

The Company's various tax positions could be challenged by the Internal Revenue Service ("IRS") at such time the Company becomes profitable. The Company has treated the acquisition of the OncoVAX® technology as the acquisition of a portfolio of assets and not as a trade or business. The Company has taken the position that the purchase price paid in stock represents a taxable acquisition under the Internal Revenue Code ("IRC") with a taxable basis in those assets equal to the fair market value of the stock paid.

In the event the Company is challenged upon receiving a tax benefit, the Company could be subject to income tax understatement penalties.

The Company has a small §382 NOL limitation due to a change in ownership. A detailed review was performed and it was determined that the §382 NOL limitation is immaterial.

Supplemental_Disclosure_of_Cas

Supplemental Disclosure of Cash Flow Information	12 Months Ended
Supplemental Disclosure of Cash Flow Information	Dec. 31, 2014
Supplemental Cash Flow Elements [Abstract]
Cash Flow, Supplemental Disclosures [Text Block]	15. Supplemental Disclosure of Cash Flow Information

	For the years ended December 31, 2014 and December 31, 2013 the Company paid interest costs of $53,279 and $308,506, respectively.

	In January 2014, the Company issued 56,075 shares of common stock, including 1,530 adjustment shares to certain holders of the 2012 Bridge Loan that had elected to convert their rights, with a value of $300,000, into common stock of the Company. The Company also issued additional Round C Warrants exercisable into 16,822 shares of common stock of the Company, with an exercise price of $6.05 per share.

	During 2014, $25,000 was converted into 4,545 shares of the Company’s common stock (Round C), 128 adjustment shares and common stock warrants (Round C Warrants) to purchase 1,363 shares of common stock (See Note 10).

	During 2013, the Company issued 170,540 shares of common stock and common stock warrants (Round C Warrants) exercisable into 51,159 shares of common stock of the Company to certain investors in the Bridge Loan who elected to convert their rights to receive cash under the Bridge Loan into shares of common stock and common stock warrants. The Company also issued an additional 4,787 adjustment shares.

Subsequent_Events

Subsequent Events	12 Months Ended
Subsequent Events	Dec. 31, 2014
Subsequent Events [Abstract]
Subsequent Events [Text Block]	16. Subsequent Events

	In accordance with ASC 855-50, “Subsequent Events,” the Company has reviewed events through the date of the filing.

	January 1, 2015 through April 3, 2015, the Company raised additional capital totaling approximately $4.2 million (net of issuance costs) through the issuance of 909,091 shares of Common Stock, 25,489 adjustment shares and warrants to purchase 272,727 shares of Common Stock.

	Vaccinogen established Vaccinogen Ireland R&D Company, Limited on January 7, 2015. The entity was established to undertake, take part in, promote, protect and encourage research, training, development, design, manufacture and production in human monoclonal antibodies, and subjects relative thereto, and to promote scientific and industrial training therein.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policies)	12 Months Ended
Summary of Significant Accounting Policies (Policies)	Dec. 31, 2014
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation

	The consolidated financial statements include the accounts of Vaccinogen, Inc. and its direct or indirect wholly owned subsidiaries, Vaccinogen BV (a company incorporated in the Netherlands); Vaccinogen (US) R&D, Inc.; Vaccinogen International Partners, LP; and Vaccinogen Bermuda, Ltd. All intercompany balances and transactions have been eliminated in consolidation.

New Accounting Pronouncements, Policy [Policy Text Block]	New Accounting Standards

	In September 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-15, Presentation of Financial Statements – Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern. The amendments in this Update define when and how companies are required to disclose going concern uncertainties, which must be evaluated each interim and annual period. Specifically, the ASU requires management to determine whether substantial doubt exists regarding the entity’s going concern presumption. Substantial doubt about an entity’s ability to continue as a going concern exists when relevant conditions and events, considered in the aggregate, indicate that it is probable that the entity will be unable to meet its obligations as they become due within one year after the date that the financial statements are issued (or available to be issued). If substantial doubt exists, certain disclosures are required; the extent of those disclosures depends on an evaluation of management’s plans (if any) to mitigate the going concern uncertainty. The new standard applies prospectively, to annual periods ending after December 15, 2016, and to annual and interim periods thereafter. Early adoption is permitted. The Company has evaluated the new standard and it is not expected to have an effect on its consolidated financial statements.

Use of Estimates, Policy [Policy Text Block]	Use of Estimates

	The preparation of consolidated financial statements in conformity with generally accepted accounting principles in the United States requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses and the disclosure of contingent assets and liabilities in its financial statements. On an ongoing basis, the Company evaluates the estimates used in recording common stock warrant related liabilities, derivative financial instruments, stock-based compensation, and where applicable, the fair value of assets. The Company may base such estimates on various assumptions which it believes to be reasonable under the circumstances. Actual results could differ from those estimates.

Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents

	The Company considers all highly liquid securities with a maturity of three months or less at acquisition to be cash equivalents. Cash and cash equivalents include demand deposits with financial institutions and at times the amounts may exceed federally insured deposit limits. The Company has not experienced any losses and does not believe it is exposed to any significant credit risk related to demand deposits.

Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]	Restricted Cash

	Restricted cash represents monies pledged by the Company’s foreign subsidiary for a lease obligation related to the manufacturing facility and to the Dutch government as required for companies with irradiator equipment.

Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentrations of Credit Risk

	Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company maintains its cash and cash equivalents with high-credit-quality financial institutions in the United States and the Netherlands.

	Cash and cash equivalents in the United States are maintained at financial institutions and, at times, balances may exceed federally insured limits. All non-interest bearing cash balances were fully insured to $250,000 per depositor at each financial institution, and noninterest bearing cash balances may again exceed federally insured limits.

	Cash and cash equivalents in The Netherlands are maintained at a financial institution and, at times, balances may exceed insured limits. Insurance coverage is limited to €100.000 for all Company accounts at each financial institution.

	The Company has not experienced any losses with respect to cash and cash equivalents.

Inventory, Policy [Policy Text Block]	Inventory

	Inventory is reported at the lower of cost or market value. The Company analyzes its inventory and writes down inventory that has become obsolete, or has a cost basis in excess of its expected net realizable value and inventory quantities in excess of expected requirements. Inventory primarily consists of a product used in creating vaccines using the OncoVAX® technology platform to be utilized in the planned phase IIIb clinical trial and for research and development activities.

Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment

	Property and equipment are recorded at cost and are depreciated or amortized over their estimated useful lives using the straight-line method. Estimated useful lives are as follows:


	Machinery and equipment	3 – 5 years
	Automobile	3 – 5 years
	Furniture and fixtures	5 years
	Computers and software	3 years
	Leasehold improvements	Shorter of lease term or useful life

	Maintenance and repairs are charged to expense as incurred. Major betterments and improvements, which extend the useful life of the underlying assets, are capitalized and depreciated.

Goodwill and Intangible Assets, Policy [Policy Text Block]	Intangible Assets

	Intangible assets consist primarily of the cost of acquired patents associated with OncoVAX® to be used in research and development and the commercialization of cancer related vaccines. The Company has capitalized the cost of the acquired patents because the Company has identified alternative future research and development efforts for numerous forms of cancer which it intends to pursue and for which management believes will result in commercialization of related vaccines. Acquired patents are carried at cost less accumulated amortization. Amortization is calculated on a straight-line basis, over the estimated useful economic life of the patent, which is 12.6 years for OncoVAX®.

Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets

	The Company accounts for the impairment of long-lived assets in accordance with ASC No. 360, Property, Plant and Equipment, which requires that long-lived assets and certain identifiable intangibles are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to future net cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amounts of the assets exceed the fair value of the assets. Assets to be disposed of are reported at the lower of the carrying amount or fair value less costs to sell. No impairment losses have been recorded in the accompanying consolidated statements of operations.

Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Translation

	The financial statements of foreign subsidiaries are maintained in their functional currency, which generally is the local currency. The assets and liabilities are translated to U.S. dollars using the exchange rate in effect at the balance sheet date. Revenues, expenses and cash flows of these operations are translated using average exchange rates during the reporting period which they occur. The resulting translation adjustments are reflected in other comprehensive loss.

Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition

	To date, the Company has not earned any revenues as the use of OncoVAX® to create cancer related vaccines still requires additional clinical trials and has not received regulatory approval for commercialization and sale.

Research and Development Expense, Policy [Policy Text Block]	Research and Development Expense

	Research and development costs are expensed as incurred. Research and development expenses primarily include the amortization of intangible assets, cost of conducting clinical trials, compensation and related overhead for employees, consultants, facilities costs and the cost of materials purchased for research and development.

Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation

	The Company measures the cost of employee services received in exchange for stock options or restricted stock awards based upon the fair value of the award on the date of the grant. The Company recognizes the estimated grant date fair value of the award as stock-based compensation expense on a straight-line basis over the requisite service period, which is generally the vesting period.

	The Company initially measures the cost of awards granted to non-employees based on the fair value of the award on the date of grant however such cost is re-measured at the end of each reporting period until performance is fully satisfied or services are rendered by the non-employee.

	The fair value of stock options granted is calculated using the Black-Scholes option-pricing model, which requires the use of subjective assumptions including volatility, expected term, risk-free rate, and the fair value of the underlying common stock. The fair value of non-vested stock awards is determined based upon the estimated fair value of the Company's common stock.

Income Tax, Policy [Policy Text Block]	Income Taxes

	Deferred income tax assets and liabilities are determined based on differences between the financial statements and tax basis of assets and liabilities, as measured using the enacted tax rates, which are expected to be in effect when the differences reverse. Valuation allowances are established when necessary to reduce deferred tax assets to the amount expected to be realized. A full valuation allowance was recorded against its deferred tax assets for the years ended December 31, 2014 and 2013, respectively.

	The tax effects of uncertain tax positions are recognized in the financial statements only if the position is more likely than not to be sustained on audit, based on the technical merits of the position. For tax positions meeting the more likely than not threshold, the amount recognized in the consolidated financial statements is the largest benefit that had greater than 50% likelihood of being realized. Management has not identified any uncertain tax positions with the exception of income tax return filing penalties and accordingly has established a liability of $100,000 and $130,000 under ASC 740-10 as of December 31, 2014 and 2013, respectively. It is the Company’s accounting policy to account for ASC 740-10 related penalties and interest by including those items in other liabilities/expenses and not in the income tax provision in the consolidated statements of operations. The Company has identified its U.S. Federal income tax return, its state return in Maryland and Netherlands corporate income tax returns as its major tax jurisdictions. Tax returns for fiscal years 2007 and forward are still open for examination.

Fair Value of Financial Instruments, Policy [Policy Text Block]	Financial Instruments

	Warrants Accounted for as Liabilities

	Abell Warrants

	In October 2011, the Company entered into a borrowing arrangement with The Abell Foundation (“Abell”). In connection with that arrangement, the Company also issued warrants (the “Abell Warrants”) exercisable into common stock of the Company. In February 2012, the Company and Abell amended the agreement to provide for additional borrowings (the “Abell Loan”). Between January 2013 and August 2014, the maturity of the Abell Loan was extended on various occasions and additional warrants were issued. The accounting treatment of these extensions is described within Note 7 to these consolidated financial statements.

	In connection with the promissory note issued to The Abell Foundation, the Company granted The Abell Foundation a security interest in its patents related to OncoVAX®. The promissory note was paid in full on August 25, 2014 and Abell released its security interest in Vaccinogen’s patents.

	The number of shares issuable pursuant to the Abell Warrants is based upon a fixed amount of $1.1 million divided by 85% of the per share price of stock sold in the next qualifying round of venture capital financing where the total proceeds are at least $35 million. The Abell Warrants have a contractual term of 10 years and were fully vested upon issuance.

	As of December 31, 2014 and 2013, the estimated fair value of the Abell Warrants was $458,537 and $1,615,835, respectively. The Company recorded a gain of approximately $1.2 million and a loss of $784,030 for the years ended December 31, 2014 and 2013, respectively.

	The Abell Warrants represent a fixed obligation that is to be settled through the issuance of a variable number of shares of the Company’s common stock. Consistent with the provisions of ASC Topic 480, Distinguishing Liabilities from Equity, the Company has concluded that the Abell Warrants should be accounted for as a liability. The Company is required to record the Abell Warrants at their estimated fair value at the end of each reporting period, with changes in the estimated fair value recorded in the consolidated statements of operations as a component of Loss on Financial Instruments.

	Abell Investment Option

	Accounting for Warrants – The Company has adopted FASB guidance related to determining whether an instrument or embedded feature is indexed to an entity’s own stock. This guidance applies to any freestanding financial instruments or embedded features that have the characteristics of a derivative, as defined in ASC Topic 815, Derivatives and hedging, and to any freestanding financial instruments that are potentially settled in an entity’s own common stock. As a result, certain warrants were considered to be derivatives and were valued using various assumptions as they are recorded as liabilities.

	On January 16, 2013, the Company entered into an investment agreement with Abell under which Abell was granted an option to acquire up to $5.0 million of common stock of the Company (the “Abell Option”). On August 22, 2014 the Company entered into a letter agreement with Abell (the “Abell Amendment”), pursuant to which Abell agreed to either (a) purchase up to 909,091 shares of the Company’s common stock at $5.50 per share, for a total of up to $5,000,000, on or before the 14th day following Abell’s receipt of written notice (together with such further related information and documentation as Abell may reasonably require) that both (i) the first patient has been given three doses of OncoVAX, with positive results (Delayed-Type Hypersensitivity), in the next phase IIIb trial and (ii) the aggregate investment by TIS of at least $40,000,000 for the purchase of our securities in accordance with the TIS Agreement has occurred or (b) surrender its investment option if the conditions above have occurred and Abell chooses not to invest within such 14 day period. TIS executed the Abell Letter Agreement for the sole purpose of affirming our commitments to (x) relocate our offices to Baltimore, Maryland within 12 months of the closing of a financing of at least $35 million and (y) to construct and maintain our next and principal manufacturing facility in Baltimore, Maryland.

	As of December 31, 2014 and 2013, the estimated fair value of the Abell Option was $0 and $7,392,528, which the Company has recorded a liability. The Company recorded a gain of $4,224,304 and a loss of $1,437,983 for the years ended December 31, 2014 and 2013, respectively.

	The Abell Investment Agreement was determined to no longer be classified as a liability as of August 22, 2014, due to changes in terms and conditions of the instrument and was reclassified to permanent equity in the amount of approximately $3.2 million.

	Derivative Financial Instruments

	The Company may enter into transactions that represent free-standing or embedded derivative financial instruments as those terms are defined in ASC Topic 815 Derivatives and Hedging (“Topic 815”). The Company records the estimated fair value of derivative financial instruments in its consolidated balance sheets and records changes in the estimated fair value of derivative financial instruments as income or expense in its consolidated statements of operations.

	Round C Warrants

	From October 2012 through December 2013 and then again from January 2014 through December 31, 2014, the Company issued warrants to certain investors in the common stock of the Company (the “Round C Warrants”). Round C Warrants to acquire 339,966 shares of common stock were issued through December 2013 and Round C Warrants to acquire 990,281 shares of common stock were issued during the year ended December 31, 2014. The Round C Warrants have an exercise price of $6.05, a contractual term of 5 years and were fully vested upon issuance.

	As of December 31, 2014 and 2013, the estimated fair value of the Round C Warrants was $1,359,647 and $1,796,427, respectively. The Company recorded a gain of $2,462,093 and a loss of $453,088 for the years ended December 31, 2014 and 2013, respectively.

	2012 Bridge Loan

	Between April 2012 and October 2012, the Company entered into transactions with various investors which resulted in the Company raising $1,019,000 from the issuance of unsecured notes payable (collectively the “Bridge Loan”). The Bridge Loan has no contractual maturity date, and is repayable only in the event that the Company closes on a future round of equity financing which results in gross proceeds of at least $20 million. If the Company fails to raise sufficient additional capital, there is no obligation to pay interest or repay any amount borrowed under the Bridge Loan. The Company did meet the $20 million threshold upon receipt of the second tranche of funding under the TIS Agreement and at that time the Company repaid an amount to the investors equal to 2 times the amount originally raised.

	The Company has classified the Bridge Loan as a derivative financial instrument, as it met the qualifying criteria of ASC Topic 815 Derivatives and Hedging (“Topic 815”) including the contractual terms whereby the Company can be required to settle its obligation under the Bridge Loan by transferring cash to investors if and only when sufficient additional capital is raised. As of December 31, 2014 and 2013, the estimated fair value of the liability associated with the Bridge Loan was $0 and $990,000 respectively, which has been recorded and included in financial instruments in the accompanying consolidated balance sheets. The Company recorded a loss of $80,000 and $389,500 for the years ended December 31, 2014 and 2013, respectively.

	The changes in the estimated fair value have been classified in Gain (Loss) on Financial Instruments in the accompanying consolidated statements of operations for the years ended December 31, 2014 and 2013.

Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share

	Basic loss per share is determined by dividing the loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. The following common stock equivalents were excluded in the calculation of diluted loss per share because their effect would be anti-dilutive:

		2014		2013

	Stock Option Pool		177,000		77,000
	Abell Investment Option		909,091		934,579
	Convertible debt		-		73,421
	Restricted stock awards		179,969		129,846
	Warrants		4,759,065		3,310,378

	Dilutive loss per share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. The net loss available to common shareholders is adjusted for gains on financial instruments, as its effect would be anti-dilutive.

		Year ended December 31, 2014
				Weighted		Loss
				Average		Per
		Net Loss		Shares		Share

	Basic loss per share	$	-8,526,805		32,760,479	$	-0.26
	Gain on derivatives		-7,753,694

	Dilutive loss per share	$	-16,280,499		32,760,479	$	-0.5

		Year ended December 31, 2013
				Weighted		Loss
				Average		Per
		Net Loss		Shares		Share

	Basic loss per share	$	-24,580,541		31,089,148	$	-0.79
	Gain on derivatives		0

	Dilutive loss per share	$	-24,580,541		31,089,148	$	-0.79

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Tables)	12 Months Ended
Summary of Significant Accounting Policies (Tables)	Dec. 31, 2014
Accounting Policies [Abstract]
Schedule of Property Plant and Equipment Estimated Useful Life [Table Text Block]	Property and equipment are recorded at cost and are depreciated or amortized over their estimated useful lives using the straight-line method. Estimated useful lives are as follows:


	Machinery and equipment	3 – 5 years
	Automobile	3 – 5 years
	Furniture and fixtures	5 years
	Computers and software	3 years
	Leasehold improvements	Shorter of lease term or useful life

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following common stock equivalents were excluded in the calculation of diluted loss per share because their effect would be anti-dilutive:

		2014		2013

	Stock Option Pool		177,000		77,000
	Abell Investment Option		909,091		934,579
	Convertible debt		-		73,421
	Restricted stock awards		179,969		129,846
	Warrants		4,759,065		3,310,378

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]	The net loss available to common shareholders is adjusted for gains on financial instruments, as its effect would be anti-dilutive.

		Year ended December 31, 2014
				Weighted		Loss
				Average		Per
		Net Loss		Shares		Share

	Basic loss per share	$	-8,526,805		32,760,479	$	-0.26
	Gain on derivatives		-7,753,694

	Dilutive loss per share	$	-16,280,499		32,760,479	$	-0.5

		Year ended December 31, 2013
				Weighted		Loss
				Average		Per
		Net Loss		Shares		Share

	Basic loss per share	$	-24,580,541		31,089,148	$	-0.79
	Gain on derivatives		0

	Dilutive loss per share	$	-24,580,541		31,089,148	$	-0.79

Property_and_Equipment_Tables

Property and Equipment (Tables)	12 Months Ended
Property and Equipment (Tables)	Dec. 31, 2014
Property, Plant and Equipment, Net [Abstract]
Property, Plant and Equipment [Table Text Block]	Property and equipment consisted of the following:

	December 31,	2014		2013

	Machinery and equipment	$	740,042	$	903,964
	Leasehold improvements		258,505		-
	Furniture and fixtures		31,764		35,690
	Computers and software		119,473		1,929
			1,149,784		941,583

	Less accumulated depreciation	$	-756,738	$	-742,793

		$	393,046	$	198,790

Intangible_Assets_Tables

Intangible Assets (Tables)	12 Months Ended
Intangible Assets (Tables)	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets [Table Text Block]	Intangible assets by major asset class were as follows at December 31, 2014:

		Gross Carrying		Accumulated		Net Carrying
		Amount		Amortization		Amount

	Intellectual Property	$	84,481,856		-28,490,967	$	55,990,889
	Other Intangible Assets		121,944		-90,544	$	31,400

		$	84,603,800		-28,581,511	$	56,022,289

	Intangible assets by major asset class were as follows at December 31, 2013:

		Gross Carrying		Accumulated		Net Carrying
		Amount		Amortization		Amount

	Intellectual Property	$	84,481,856		-21,792,439	$	62,689,417
	Other Intangible Assets		121,944		-85,802		36,142

		$	84,603,800		-21,878,241	$	62,725,559

Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	The estimated future amortization relating to all intangible assets that are recorded in the consolidated balance sheets as of December 31, 2014 is as follows:

	Years ending December 31,

	2015	$	6,702,516
	2016		6,702,516
	2017		6,702,516
	2018		6,702,516
	2019		6,702,516
	Thereafter		22,509,709

		$	56,022,289

Prepaid_Expenses_and_Other_Cur1

Prepaid Expenses and Other Current Assets (Tables)	12 Months Ended
Prepaid Expenses and Other Current Assets (Tables)	Dec. 31, 2014
Prepaid Expense and Other Assets, Current [Abstract]
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	Prepaid expenses and other current assets consisted of the following:

	December 31,	2014		2013

	Prepaid Clinical Trial expense	$	2,477,571	$	-
	Prepaid Other		432,905		115,522
		$	2,910,476	$	115,522

Notes_Payable_Tables

Notes Payable (Tables)	12 Months Ended
Notes Payable (Tables)	Dec. 31, 2014
Notes Payable [Abstract]
Schedule of Short-term Debt [Table Text Block]	December 31,	2014		2013

	Organon Obligation	$	3,000,000	$	3,500,000
	Abell Loan		-		1,331,217

		$	3,000,000	$	4,831,217

Fair_Value_Measurements_Tables

Fair Value Measurements (Tables)	12 Months Ended
Fair Value Measurements (Tables)	Dec. 31, 2014
Fair Value Disclosures [Abstract]
Fair Value, Liabilities Measured on Recurring Basis [Table Text Block]	The Company’s financial instruments measured on a recurring basis using fair value estimates are as follows:

					December 31, 2014
	Description	Total			Level 1			Level 2			Level 3

	Abell Warrants	$	438,537		$	-		$	-		$	438,537
	Round C Warrants		1,359,647			-			-			1,359,647

		$	1,798,184		$	-		$	-		$	1,798,184

					December 31, 2013
	Description	Total			Level 1			Level 2			Level 3

	Abell Warrants	$	1,615,835		$	-		$	-		$	1,615,835
	Round C Warrants		1,796,427			-			-			1,796,427
	Bridge Loan		990,000			-			-			990,000
	Abell Investment Option		7,392,528			-			-			7,392,528

		$	11,794,790		$	-		$	-		$	11,794,790

Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	The following is a reconciliation of the fair value measurements from January 1, 2013 to December 31, 2014.

		Abell			Round C			Bridge			Abell
		Warrants			Warrants			Loan			Option

	Balance, January 1, 2013	$	831,806		$	230,349		$	1,528,500		$	-
	Issuance of securities		275,813			1,112,990			-938,000			5,954,545
	Fair value change included in earnings		508,216			453,088			399,500			1,437,983

	Balance, December 31, 2013		1,615,835			1,796,427			990,000			7,392,528
	Issuance of securities		37,529			2,025,313			-			-
	Repayment/extinguishment of debt		-			-			-1,100,000			-3,168,224
	Fair value change included in earnings		-1,214,827			-2,462,093			110,000			-4,224,304

	Balance, December 31, 2014	$	438,537		$	1,359,647		$	-		$	-

Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	Quantitative information as of December 31, 2014 with respect to financial instruments measured and carried at fair value on a recurring basis with the use of significant unobservable inputs (Level 3) are as follows:

	Level 3 - Significant Unobservable Inputs
	Description	Fair Value			Principal Valuation		Unobservable		Range
					Techniques		Inputs		(Weighted
									Average)

	Abell Warrants	$	438,537		Black-Scholes		Strike price Equity volatility		N/A
	Round C Warrants	$	1,359,647		Black-Scholes		Strike price Equity volatility		N/A

Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Table Text Block]	The fair value of the Abell Warrants and the Round C Warrants are estimated at the end of each reporting period using an option pricing model. More specifically, the Black-Scholes option pricing model was utilized in the valuation of both the Abell Warrants and the Round C Warrants. The following assumptions were used:

		Abell Warrants								Round C Warrants
		2014				2013				2014			2013

	Volatility		94	%			80	%			87	%		80	%
	Exercise price	$	4.55			$	4.68			$	5.88		$	5.88
	Stock price at December 31	$	2.2			$	7.91			$	2.2		$	7.91
	Risk free interest rate		2.17	%			3.04	%			1.02% - 1.65	%		1.13% - 1.75	%
	Dividend yield		0	%			0	%			0	%		0	%
	Expected life		10				10				2.8 -5.0			3.7 -5.0

StockBased_Compensation_Tables

Stock-Based Compensation (Tables)	12 Months Ended
Stock-Based Compensation (Tables)	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity [Table Text Block]	The weighted average fair values for the awards below are based on the fair value at the grant date of the respective awards, which is equal to the value of the Company’s common stock on such date.

			2014						2013
						Weighted						Weighted
						Average Fair						Average Fair
			Shares			Value			Shares			Value

	Balance, beginning of year			129,846		$	3.77			119,734		$	3.42
	Granted			50,123		$	2.2			10,112		$	7.91
	Vested			-		$	-			-		$	-
	Forfeitures			-		$	-			-		$	-

	Balance, end of year			179,969		$	3.35			129,846		$	3.77

Schedule Of Fair Value Assumptions [Table Text Block]	The Company uses the Black-Scholes option pricing model to calculate the fair value of options. The significant assumptions for options issued in 2014, used in this model include:

	Annual Dividend	-
	Expected life (in years)	6.25 – 10.00
	Risk free interest rate	1.35% - 2.17%
	Expected volatility	80%

Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block]	The following table summarizes the Stock Option pool activity for 2014.

						Weighted			Weighted
						Average			Average
			Shares			Exercise			Remaining
			Shares			Price			Life

	Balance, beginning of year			77,000		$	7			-
	Granted			100,000		$	3.64			-
	Forfeited			-		$	-			-
	Balance, end of year			177,000		$	6.44			8.72

Schedule Of Share Based Compensation Arrangements By Share Based Payment Award Warrants [Table Text Block]	The following table summarizes the stock purchase warrant activity for 2014 and 2013.

			2014						2013
						Weighted						Weighted
						Average						Average
			Shares			Fair			Shares			Fair
			Shares			Value			Shares			Value

	Balance, beginning of year			785,575		$	1.48			785,575		$	1.48
	Granted			35,000		$	4.22			-		$	-

	Balance, end of year			820,575		$	1.6			785,575		$	1.48

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table summarizes information on stock purchase warrants outstanding as of December 31, 2014:

	Exercise price			Shares			Weighted			Weighted
							Average			Average
							Remaining			Exercise
							Life			Price

	$	1			705,575			1.05		$	1
	$	5.5			80,000			3.74		$	5.5
	$	7.5			35,000			4.34		$	7.5

		Total			820,575			2.35		$	1.72

Schedule Of Warrants Activity [Table Text Block]	The following table summarizes the warrant activity for 2013 and 2014 and is inclusive of the Abell Warrants, the Round C Warrants, the Stock Purchase Warrants and represents the total outstanding warrants.

			Shares			Weighted			Weighted
						Average			Average
						Exercise Price			Remaining Life
	Outstanding at January 1, 2013			2,663,648		$	1.48			1.81
	Granted			646,730		$	5.2			7.66
	Exercised			-		$	-			-
	Expired			-		$	-			-
	Outstanding at December 31, 2013			3,310,378		$	2.2			2.95
	Granted			1,448,687		$	5.69			5.91
	Exercised			-		$	-			-
	Expired			-		$	-			-
	Outstanding at December 31, 2014			4,759,065		$	1.73			3.77

Summary Of Outstanding Warrants By Year Of Expiration [Table Text Block]	The following table summarizes the outstanding warrants by year of expiration:

			Shares
	2015			1,151,690
	2016			1,201,475
	2017			59,439
	2018			360,527
	2019			765,861
	Thereafter			1,220,073
	Total			4,759,065

Commitments_and_Contingencies_

Commitments and Contingencies (Tables)	12 Months Ended
Commitments and Contingencies (Tables)	Dec. 31, 2014
Commitments and Contingencies Disclosure [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Minimum future lease payments under non-cancelable operating leases, at December 31, 2014 were as follows:

	For year ended December 31,	Amount
	2015	$	210,887
	2016		210,170
	2017		214,297
	2018		89,950
	Total	$	725,304

Income_Taxes_Tables

Income Taxes (Tables)	12 Months Ended
Income Taxes (Tables)	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The Company is subject to U.S. Federal, state and foreign income taxes. The provision/(benefit) for income taxes for the tax years ended December 31, 2014 and 2013 are as follows:

		December 31,
		2014		2013

	Current:
	Federal	$	206,568	$	-
	State		31,649		-
	Foreign		-		-

	Total Current		238,217		-

	Deferred:
	Federal		-3,932,476		-4,466,979
	State		-629,774		-715,374
	Foreign		-223,923		-165,845

	Total Deferred (Provision)/Benefit		-4,786,173		-5,348,198
	Valuation Allowance		4,786,173		5,348,198

	Total Tax Provision/(Benefit)	$	238,217	$	-

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	A reconciliation of the U.S. federal statutory income tax rate to the Company’s consolidated effective income tax rate for the years ended December 31, 2014 and 2013 is as follows:

	Effective Rate Reconciliation
	Years ended	12/31/14			12/31/13

	Income tax at statutory rate	34%			34%
	Financial instruments	32%			-12%
	State taxes - (net of fed)	5%			3%
	International rate difference	-10%			-1%
	Amortization of prepaid	-3%			0%
	Change-valuation allowance - fed	-64%			-22%
	All other items	3%			-2%
	Effective income tax rate	-3%			0%

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The Company’s deferred income tax assets and liabilities as of December 31, 2014 and 2013 were as follows:

	Start-up expenditures and amortization		8,036,569		5,910,419
	Amortization of intangibles		4,996,993		8,631,105
	Financial instruments		1,408,087		705,008
	Nonqualified stock options		478,061		343,372
	U.S. net operating loss		-		2,576,756
	Foreign net operating loss		2,020,627		1,796,704
	Total long-term deferred income taxes:		16,940,337		19,963,364
	Valuation allowance		-16,940,337		-19,963,364
	Total Current and Deferred Income Tax Assets/(Liabilities)	$	-	$	-

Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]	The remaining unrecognized benefits represent federal and state taxes on intercompany transactions between the Company and its international subsidiaries.

		2014		2013
	Unrecognized tax benefits, beginning of the year	$	130,000	$	90,000
	Decreases for tax positions related to prior years		-30,000		-
	Increases for tax positions taken during the year		8,814,027		40,000
	Unrecognized tax benefits, end of the year	$	8,914,027	$	130,000

Going_Concern_Details_Textual

Going Concern (Details Textual) (USD $)	1 Months Ended	12 Months Ended
Going Concern (Details Textual) (USD $)	Apr. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Nov. 11, 2014
Retained Earnings (Accumulated Deficit), Total		-111,806,126	($103,279,321)
Working Capital		1,000,000
The Investment Syndicate [Member]
Payments for Remaining milestones	60,000,000
Description on investment units		the remaining $60,000,000 shortly after consummation of the second closing
Description on remaining investment units		(with the final $20,000,000 to be held in escrow pending fulfillment of the milestone contained in the TIS Agreement relating to the first patient receiving the first three doses of OncoVax, with positive results).
Investments in and Advances to Affiliates, Balance, Principal Amount				10,000,000
Common Stock Value Reserved For Future Issuance	80,000,000
Sale of Stock, Consideration Received on Transaction	20,000,000
Additional Option To Invest Expired Amount				$30,000,000

Summary_of_Significant_Account3

Summary of Significant Accounting Policies (Details)	12 Months Ended
Summary of Significant Accounting Policies (Details)	Dec. 31, 2014
Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Computers and software [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Estimated Useful Lives	Shorter of lease term or useful life
Minimum [Member] \| Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Minimum [Member] \| Automobiles [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member] \| Machinery and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years
Maximum [Member] \| Automobiles [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life	5 years

Summary_of_Significant_Account4

Summary of Significant Accounting Policies (Details 1)	12 Months Ended
Summary of Significant Accounting Policies (Details 1)	Dec. 31, 2014	Dec. 31, 2013
Stock Option Pool [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	177,000	77,000
Abell Investment Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	909,091	934,579
Convertible debt [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	0	73,421
Restricted stock awards [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	179,969	129,846
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	4,759,065	3,310,378

Summary_of_Significant_Account5

Summary of Significant Accounting Policies (Details 2) (USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Basic loss per share, Net Loss	($8,526,805)	($24,580,541)
Gain on derivatives, Net Loss	-7,753,694	3,074,600
Dilutive loss per share, Net Loss	($16,280,499)	($24,580,541)
Basic loss per share, Weighted Average Shares	32,760,479	31,089,148
Dilutive loss per share, Weighted Average Shares	32,760,479	31,089,148
Basic loss per share	($0.26)	($0.79)
Dilutive loss per share	($0.50)	($0.79)

Summary_of_Significant_Account6

Summary of Significant Accounting Policies (Details Textual)

1 Months Ended

7 Months Ended

12 Months Ended

0 Months Ended

1 Months Ended

12 Months Ended

Aug. 31, 2014

Oct. 31, 2011

Oct. 31, 2012

Dec. 31, 2014

Dec. 31, 2013

Aug. 31, 2012

Dec. 31, 2014

Dec. 31, 2013

Jan. 16, 2013

Aug. 22, 2014

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

Dec. 31, 2013

Dec. 31, 2014

USD ($)

EUR (€)

USD ($)

Bridge Loan [Member]

Abell Investment Option [Member]

Abell Option [Member]

Abell Warrant [Member]

Round C Warrant [Member]

Patents [Member]

USD ($)

Malpractice Insurance, Annual Coverage Limit

$250,000

€ 100

Finite-Lived Intangible Asset, Useful Life

12 years 7 months 6 days

Debt Instrument, Convertible, Terms of Conversion Feature

The number of shares issuable pursuant to the Abell Warrants is based upon a fixed amount of $1.1 million divided by 85% of the per share price of stock sold in the next qualifying round of venture capital financing where the total proceeds are at least $35 million.

Warrants Contractual Term

5 years

10 years

Fair Value, Option, Changes in Fair Value, Gain (Loss)

80,000

389,500

4,224,304

1,437,983

1,200,000

784,030

2,462,093

453,088

Financial Liabilities Fair Value Disclosure, Total

1,798,184

11,794,790

7,392,528

Debt Instrument, Convertible, Number of Equity Instruments

990,281

339,966

Class of Warrant or Right, Exercise Price of Warrants or Rights

$6.05

Proceeds from Unsecured Notes Payable

1,019,000

Debt Instrument, Convertible, Carrying Amount of Equity Component

20,000,000

Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross value

5,000,000

Unrecognized Tax Benefits, Interest on Income Taxes Accrued

100,000

130,000

Warrants Not Settleable in Cash, Fair Value Disclosure

990,000

458,537

1,615,835

1,359,647

1,796,427

Common stock purchase

909,091

Common stock, par value (in dollars per share)

$5.50

$0.00

$5.50

Total shares of common stock

-909,091

5,000,000

Purchase of securities

40,000,000

Closing financing cost

35,000,000

Reclassifications of Temporary to Permanent Equity

$3,200,000

Agreements_with_Intracel_Detai

Agreements with Intracel (Details Textual) (USD $)	1 Months Ended
Agreements with Intracel (Details Textual) (USD $)	Oct. 31, 2007	Aug. 22, 2014	Dec. 31, 2014	Dec. 31, 2013	Aug. 31, 2012	Dec. 31, 2010	Jun. 30, 2010	Oct. 10, 2007	Jun. 24, 2010	Apr. 10, 2015
Agreement [Line Items]
Common Stock, Shares, Issued			34,962,172	31,568,629	200,000,000
Common Stock, Value, Issued			$3,496	$3,157
Preferred Stock, Shares Issued			0	0
Preferred Stock, Value, Issued			0	0
Milestone [Member]
Agreement [Line Items]
Equity Method Investment, Ownership Percentage			50.00%
Series B Preferred Stock [Member]
Agreement [Line Items]
Equity Method Investment, Ownership Percentage						50.00%
Assets Transfer Agreement [Member] \| Series B Preferred Stock [Member]
Agreement [Line Items]
Preferred Stock, Shares Issued						10,973,612	3,452,766
Preferred Stock, Value, Issued						63,100,000	16,800,000
License Agreement Terms [Member]
Agreement [Line Items]
Equity Method Investment, Ownership Percentage								10.00%
Liabilities Assumed	4,000,000
Common Stock, Shares, Issued			1,506,750
Common Stock, Value, Issued			984,000
Equity, Fair Value Disclosure, Total			4,450,000
License Agreement Terms [Member] \| Series B Preferred Stock [Member]
Agreement [Line Items]
Equity Method Investment, Ownership Percentage									20.00%
License Agreement Terms [Member] \| Common Stock And Series AA Preferred Stock [Member]
Agreement [Line Items]
Equity Method Investment, Ownership Percentage									10.00%
Trade Payable [Member]
Agreement [Line Items]
Settlement Liabilities, Current								450,000
Intracel Ltd [Member]
Agreement [Line Items]
Equity Method Investment, Ownership Percentage										37.00%
Liabilities Assumed		$80,000,000
Intracel Ltd [Member] \| Officers and Directors [Member]
Agreement [Line Items]
Equity Method Investment, Ownership Percentage										37.00%
Intracel Ltd [Member] \| Series B Preferred Stock [Member]
Agreement [Line Items]
Equity Method Investment, Ownership Percentage			20.00%
Stock Holder One [Member]
Agreement [Line Items]
Equity Method Investment, Ownership Percentage								10.00%

Property_and_Equipment_Details

Property and Equipment (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Property Plant And Equipment Gross	$1,149,784	$941,583
Less accumulated depreciation	-756,738	-742,793
Property, Plant and Equipment, Net ,Total	393,046	198,790
Machinery and equipment [Member]
Property, Plant and Equipment [Line Items]
Property Plant And Equipment Gross	740,042	903,964
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property Plant And Equipment Gross	258,505	0
Furniture and fixtures [Member]
Property, Plant and Equipment [Line Items]
Property Plant And Equipment Gross	31,764	35,690
Computers and software [Member]
Property, Plant and Equipment [Line Items]
Property Plant And Equipment Gross	$119,473	$1,929

Property_and_Equipment_Details1

Property and Equipment (Details Textual) (USD $)	12 Months Ended
Property and Equipment (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Property, Plant and Equipment [Line Items]
Depreciation	$51,723	$24,165

Intangible_Assets_Details

Intangible Assets (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$84,603,800	$84,603,800
Accumulated Amortization	-28,581,511	-21,878,241
Net Carrying Amount	56,022,289	62,725,559
Intellectual Property [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	84,481,856	84,481,856
Accumulated Amortization	-28,490,967	-21,792,439
Net Carrying Amount	55,990,889	62,689,417
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	121,944	121,944
Accumulated Amortization	-90,544	-85,802
Net Carrying Amount	$31,400	$36,142

Intangible_Assets_Details_1

Intangible Assets (Details 1) (USD $)	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
2015	$6,702,516
2016	6,702,516
2017	6,702,516
2018	6,702,516
2019	6,702,516
Thereafter	22,509,709
Finite-Lived Intangible Assets, Net, Total	$56,022,289

Intangible_Assets_Details_Text

Intangible Assets (Details Textual) (USD $)	12 Months Ended
Intangible Assets (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets	$6,703,270	$6,703,272
Finite-Lived Intangible Assets, Remaining Amortization Period	12 years 7 months 6 days

Prepaid_Expenses_and_Other_Cur2

Prepaid Expenses and Other Current Assets (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Prepaid Expense And Other Assets Current [Line Items]
Prepaid Clinical Trial expense	$2,477,571	$0
Prepaid Other	432,905	115,522
Prepaid Expense Current	$2,910,476	$115,522

Prepaid_Expenses_and_Other_Cur3

Prepaid Expenses and Other Current Assets (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Prepaid Expense And Other Assets Current [Line Items]
Prepaid Expense, Current	$2,910,476	$115,522
Clinical Research Organization CRO [Member]
Prepaid Expense And Other Assets Current [Line Items]
Prepaid Expense, Current	$2,400,000

Notes_Payable_Details

Notes Payable (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Short-term Debt [Line Items]
Notes Payable, Current	$0	$4,831,217
Organon Obligation [Member]
Short-term Debt [Line Items]
Notes Payable, Current	3,000,000	3,500,000
Abell Loan [Member]
Short-term Debt [Line Items]
Notes Payable, Current	$0	$1,331,217

Notes_Payable_Details_Textual

Notes Payable (Details Textual) (USD $)	0 Months Ended	12 Months Ended		1 Months Ended
Notes Payable (Details Textual) (USD $)	Feb. 16, 2012	Dec. 31, 2014	Dec. 31, 2013	Oct. 31, 2007	Nov. 01, 2014	Oct. 31, 2008	Dec. 31, 2007	Apr. 26, 2012	Oct. 26, 2011
Short-term Debt [Line Items]
Debt Instrument, Periodic Payment, Interest		$140,000
Interest Paid, Total		53,279	308,506
Debt Instrument, Increase (Decrease), Net, Total	1,800,000
Interest Expense, Debt, Excluding Amortization		400,000
Adjustments to Additional Paid in Capital, Other		1,818,642	1,751,108
Other Income [Member]
Short-term Debt [Line Items]
Debt Instrument Periodic Payment Principal Due					500,000
Organon Obligation [Member]
Short-term Debt [Line Items]
Long-term Debt, Gross				3,500,000			4,000,000
Debt Instrument, Periodic Payment, Principal				500,000
Debt Instrument, Increase, Accrued Interest				500,000
Debt Instrument, Periodic Payment, Interest				500,000
Debt Instrument, Annual Principal Payment				1,000,000
Debt Instrument, Interest Rate, Stated Percentage						4.00%
Interest Paid, Total		136,666	96,314
Abell Loan [Member]
Short-term Debt [Line Items]
Interest Paid, Total		48,000	133,000
Class Of Warrants or Rights Issued			300,000
Abell Loan [Member] \| Working Capital Loan [Member]
Short-term Debt [Line Items]
Long-term Debt, Gross									1,500,000
Debt Instrument, Interest Rate, Stated Percentage								8.00%
Abell Loan [Member] \| Additional Loan [Member]
Short-term Debt [Line Items]
Long-term Debt, Gross	$300,000

Fair_Value_Measurements_Detail

Fair Value Measurements (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Liabilities, Fair Value Disclosure, Recurring	$1,798,184	$11,794,790
Fair Value, Inputs, Level 1 [Member]
Liabilities, Fair Value Disclosure, Recurring	0	0
Fair Value, Inputs, Level 2 [Member]
Liabilities, Fair Value Disclosure, Recurring	0	0
Fair Value, Inputs, Level 3 [Member]
Liabilities, Fair Value Disclosure, Recurring	1,798,184	11,794,790
Abell Warrants [Member]
Liabilities, Fair Value Disclosure, Recurring	438,537	1,615,835
Abell Warrants [Member] \| Fair Value, Inputs, Level 1 [Member]
Liabilities, Fair Value Disclosure, Recurring	0	0
Abell Warrants [Member] \| Fair Value, Inputs, Level 2 [Member]
Liabilities, Fair Value Disclosure, Recurring	0	0
Abell Warrants [Member] \| Fair Value, Inputs, Level 3 [Member]
Liabilities, Fair Value Disclosure, Recurring	438,537	1,615,835
Round C Warrants [Member]
Liabilities, Fair Value Disclosure, Recurring	1,359,647	1,796,427
Round C Warrants [Member] \| Fair Value, Inputs, Level 1 [Member]
Liabilities, Fair Value Disclosure, Recurring	0	0
Round C Warrants [Member] \| Fair Value, Inputs, Level 2 [Member]
Liabilities, Fair Value Disclosure, Recurring	0	0
Round C Warrants [Member] \| Fair Value, Inputs, Level 3 [Member]
Liabilities, Fair Value Disclosure, Recurring	1,359,647	1,796,427
Bridge Loan [Member]
Liabilities, Fair Value Disclosure, Recurring		990,000
Bridge Loan [Member] \| Fair Value, Inputs, Level 1 [Member]
Liabilities, Fair Value Disclosure, Recurring		0
Bridge Loan [Member] \| Fair Value, Inputs, Level 2 [Member]
Liabilities, Fair Value Disclosure, Recurring		0
Bridge Loan [Member] \| Fair Value, Inputs, Level 3 [Member]
Liabilities, Fair Value Disclosure, Recurring		990,000
Abell Investment Option [Member]
Liabilities, Fair Value Disclosure, Recurring		7,392,528
Abell Investment Option [Member] \| Fair Value, Inputs, Level 1 [Member]
Liabilities, Fair Value Disclosure, Recurring		0
Abell Investment Option [Member] \| Fair Value, Inputs, Level 2 [Member]
Liabilities, Fair Value Disclosure, Recurring		0
Abell Investment Option [Member] \| Fair Value, Inputs, Level 3 [Member]
Liabilities, Fair Value Disclosure, Recurring		$7,392,528

Fair_Value_Measurements_Detail1

Fair Value Measurements (Details 1) (USD $)	12 Months Ended
Fair Value Measurements (Details 1) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Abell Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning Balance	$1,615,835	$831,806
Issuance of securities	37,529	275,813
Repayment/extinguishment of debt	0
Fair value change included in earnings	-1,214,827	508,216
Ending Balance	438,537	1,615,835
Round C Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning Balance	1,796,427	230,349
Issuance of securities	2,025,313	1,112,990
Repayment/extinguishment of debt	0
Fair value change included in earnings	-2,462,093	453,088
Ending Balance	1,359,647	1,796,427
Bridge Loan [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning Balance	990,000	1,528,500
Issuance of securities	0	-938,000
Repayment/extinguishment of debt	-1,100,000
Fair value change included in earnings	110,000	399,500
Ending Balance	0	990,000
Abell Investment Option [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning Balance	7,392,528	0
Issuance of securities	0	5,954,545
Repayment/extinguishment of debt	-3,168,224
Fair value change included in earnings	-4,224,304	1,437,983
Ending Balance	$0	$7,392,528

Fair_Value_Measurements_Detail2

Fair Value Measurements (Details 2) (USD $)	12 Months Ended
Fair Value Measurements (Details 2) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Liabilities, Fair Value Disclosure, Recurring	$1,798,184	$11,794,790
Round C Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Liabilities, Fair Value Disclosure, Recurring	1,359,647	1,796,427
Bridge Loan [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Liabilities, Fair Value Disclosure, Recurring		990,000
Fair Value, Inputs, Level 3 [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Liabilities, Fair Value Disclosure, Recurring	1,798,184	11,794,790
Fair Value, Inputs, Level 3 [Member] \| Abell Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Liabilities, Fair Value Disclosure, Recurring	438,537
Fair Value Measurements, Valuation Techniques	Black-Scholes
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings, Description	Strike price Equity volatility
Fair Value, Inputs, Level 3 [Member] \| Round C Warrants [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Liabilities, Fair Value Disclosure, Recurring	1,359,647	1,796,427
Fair Value Measurements, Valuation Techniques	Black-Scholes
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings, Description	Strike price Equity volatility
Fair Value, Inputs, Level 3 [Member] \| Bridge Loan [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Liabilities, Fair Value Disclosure, Recurring		$990,000

Fair_Value_Measurements_Detail3

Fair Value Measurements (Details 3) (USD $)	12 Months Ended
Fair Value Measurements (Details 3) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price at December 31	$5.35
Abell Warrants [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility	94.00%	80.00%
Exercise price	$4.55	$4.68
Stock price at December 31	$2.20	$7.91
Risk free interest rate	2.17%	3.04%
Dividend yield	0.00%	0.00%
Expected life	10 years	10 years
Round C Warrants [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Volatility	87.00%	80.00%
Exercise price	$5.88	$5.88
Stock price at December 31	$2.20	$7.91
Dividend yield	0.00%	0.00%
Maximum [Member] \| Round C Warrants [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price at December 31	$1.65	$1.75
Expected life	5 years	5 years
Minimum [Member] \| Round C Warrants [Member]
Fair Value Measurements, Recurring and Nonrecurring, Valuation Techniques [Line Items]
Stock price at December 31	$1.02	$1.13
Expected life	2 years 9 months 18 days	3 years 8 months 12 days

Fair_Value_Measurements_Detail4

Fair Value Measurements (Details Textual) (USD $)	1 Months Ended	0 Months Ended	12 Months Ended
Fair Value Measurements (Details Textual) (USD $)	Aug. 31, 2014	Jan. 16, 2013	Dec. 31, 2014	Dec. 31, 2013	Aug. 31, 2012
Shares Issued, Price Per Share		$5.50
Discounted Share Price Per Share		$4.40	$5.35
Investment Owned, Face Amount		$5,000,000
Yielded Number Of Shares		1,136,364	934,580
Stock Issued During Period, Value, Share-based Compensation, Gross	5,000,000
Common Stock, Par or Stated Value Per Share	$5.50		$0.00	$0.00	$0.00
Total shares of common stock	-909,091
Abell Investment Option [Member]
Stock Issued During Period, Value, Share-based Compensation, Gross	$3,168,224

Stockholders_Equity_Details_Te

Stockholders' Equity (Details Textual) (USD $)	12 Months Ended
Stockholders' Equity (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Aug. 31, 2014	Aug. 31, 2012
Common Stock, Par or Stated Value Per Share	$0.00	$0.00	$5.50	$0.00
Preferred Stock, Shares Authorized	50,000,000	50,000,000		50,000,000
Preferred Stock, Par or Stated Value Per Share	$0.00	$0.00		$0.00
Common Stock, Shares, Issued	34,962,172	31,568,629		200,000,000
Proceeds From Issuance of Common Stock Warrants	$1,947,224
Share Price	$5.35
Stock Issued During Period Shares Prior To Antidilution Protection	27,213
Stock Issued During Period Shares After Antidilution Protection	92,581
Additional Paid in Capital, Total	164,844,066	143,920,855
Placement Agent [Member]
Payments for Commissions	682,390	25,288
Round C Warrants [Member]
Common Stock, Shares, Issued	5,600,000
Proceeds From Issuance of Common Stock Warrants	30,800,000	926,581
Adjustments to Additional Paid in Capital, Warrant Issued	90,923	21,465
Proceeds from Issuance of Common Stock	18,966
Debt Conversion, Converted Instrument, Warrants or Options Issued	128
Round C Warrants [Member] \| Bridge Loan [Member]
Proceeds From Issuance of Common Stock Warrants	72,061
Stock And Warrants Issued To Purchase Common Stock	1,363
Proceeds from Issuance of Common Stock		751,561
Debt Conversion, Converted Instrument, Warrants or Options Issued	1,530	4.787
Round C Stock [Member]
Proceeds From Issuance of Common Stock Warrants	6,034
Anti-Dilution Protection Description	The Company filed a Form S-1 Registration Statement with the SEC, which became effective on October 31, 2013. The market price ofVaccinogen stock as of that date was $5.35. Pursuant to the protection provided to subscribers prior to October 31, 2013, 27,213 adjustment shares were issued. All subscriptions subsequent to the October 31, 2013 effective date through December 31, 2013 have been issued adjustment shares, totaling 92,581 adjustment shares, for the year ended December 31, 2014. All of the adjustment shares are included in the calculation of total shares issued or outstanding for the years ended December 31, 2014 and 2013.
Additional Paid in Capital, Total	17,830,303	4,205,105
Stock Issued During Period, Shares, New Issues	3,246,417	764,578
Stock And Warrants Issued To Purchase Common Stock	972,525	229,368
Proceeds from Issuance of Common Stock	15,200,689	3,253,316
Debt Conversion, Converted Instrument, Amount	25,000
Debt Conversion, Converted Instrument, Shares Issued	4,545
Round C Stock [Member] \| Bridge Loan [Member]
Proceeds From Issuance of Common Stock Warrants		186,409
Proceeds from Issuance of Common Stock	227,939
Debt Conversion, Converted Instrument, Amount	$300,000	$937,970
Debt Conversion, Converted Instrument, Shares Issued	54,545	170,540
Stock And Warrants Issued To Exercise Common Stock	16,363
Round C Stock And Round C Warrants [Member] \| Bridge Loan [Member]
Stock And Warrants Issued To Exercise Common Stock		51,159

StockBased_Compensation_Detail

Stock-Based Compensation (Details) (Restricted Stock [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Restricted Stock [Member]
Options, Outstanding Shares
Balance, beginning of year	129,846	119,734
Granted	50,123	10,112
Vested	0	0
Forfeitures	0	0
Balance, end of year	179,969	129,846
Weighted Average Fair Value
Balance, beginning of year	$3.77	$3.42
Granted	$2.20	$7.91
Vested	$0	$0
Forfeitures	$0	$0
Balance, end of year	$3.35	$3.77

StockBased_Compensation_Detail1

Stock-Based Compensation (Details 1)	12 Months Ended
Stock-Based Compensation (Details 1)	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Annual Dividend	0.00%
Expected volatility	80.00%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)	10 years
Risk free interest rate	2.17%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)	6 years 3 months
Risk free interest rate	1.35%

StockBased_Compensation_Detail2

Stock-Based Compensation (Details 2) (USD $)	12 Months Ended
Stock-Based Compensation (Details 2) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Weighted Average Exercise Price
Balance, end of year	$1.72
Stock Option Pool [Member]
Options, Outstanding Shares
Balance, beginning of year	77,000
Granted	100,000
Forfeited	0
Balance, end of year	177,000	77,000
Weighted Average Exercise Price
Balance, beginning of year	$7
Granted	$3.64
Forfeited	$0
Balance, end of year	$6.44	$7
Weighted Average Remaining Life
Balance, beginning of year	8 years 8 months 19 days	0 years
Granted	0 years
Forfeited	0 years
Balance, end of year	8 years 8 months 19 days	0 years

StockBased_Compensation_Detail3

Stock-Based Compensation (Details 3) (Warrant Activity [Member], USD $)	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013
Warrant Activity [Member]
Shares
Balance, beginning of year	785,575	785,575
Granted	35,000	0
Balance, end of year	820,575	785,575
Weighted Average Fair Value
Balance, beginning of year	$1.48	$1.48
Granted	$4.22	$0
Balance, end of year	$1.60	$1.48

StockBased_Compensation_Detail4

Stock-Based Compensation (Details 4) (USD $)	12 Months Ended
Stock-Based Compensation (Details 4) (USD $)	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Shares	820,575
Warrants Outstanding, Weighted Average remaining life	2 years 4 months 6 days
Warrants Outstanding, Weighted Average Exercise Price	$1.72
Exercise Price 1.00 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Shares	705,575
Warrants Outstanding, Weighted Average remaining life	1 year 18 days
Warrants Outstanding, Weighted Average Exercise Price	$1
Exercise Price 5.50 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Shares	80,000
Warrants Outstanding, Weighted Average remaining life	3 years 8 months 26 days
Warrants Outstanding, Weighted Average Exercise Price	$5.50
Exercise Price 7.50 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Shares	35,000
Warrants Outstanding, Weighted Average remaining life	4 years 4 months 2 days
Warrants Outstanding, Weighted Average Exercise Price	$7.50

StockBased_Compensation_Detail5

Stock-Based Compensation (Details 5) (USD $)	12 Months Ended
Stock-Based Compensation (Details 5) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Weighted Average Exercise Price
Balance, end of year	$1.72
Total Warrant Activity [Member]
Options, Outstanding Shares
Balance, beginning of year	3,310,378	2,663,648
Granted	1,448,687	646,730
Exercised	0	0
Expired	0	0
Balance, end of year	4,759,065	3,310,378	2,663,648
Weighted Average Exercise Price
Balance, beginning of year	$2.20	$1.48
Granted	$5.69	$5.20
Exercised	$0	$0
Expired	$0	$0
Balance, end of year	$1.73	$2.20	$1.48
Weighted Average Remaining Life
Balance, beginning of year	3 years 9 months 7 days	2 years 11 months 12 days	1 year 9 months 22 days
Granted	5 years 10 months 28 days	7 years 7 months 28 days
Exercised	0 years	0 years
Expired	0 years	0 years
Balance, end of year	3 years 9 months 7 days	2 years 11 months 12 days	1 year 9 months 22 days

StockBased_Compensation_Detail6

Stock-Based Compensation (Details 6)	12 Months Ended
Stock-Based Compensation (Details 6)	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Of Warrants Outstanding Expire	4,759,065
Two Thousand Fifteen Year [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Of Warrants Outstanding Expire	1,151,690
Two Thousand Sixteen Year [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Of Warrants Outstanding Expire	1,201,475
Two Thousand Seventeen Year [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Of Warrants Outstanding Expire	59,439
Two Thousand Eighteen Year [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Of Warrants Outstanding Expire	360,527
Two Thousand Nineteen Year [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Of Warrants Outstanding Expire	765,861
After Two Thousand Nineteen Year [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Of Warrants Outstanding Expire	1,220,073

StockBased_Compensation_Detail7

Stock-Based Compensation (Details Textual) (USD $)	12 Months Ended			53 Months Ended
Stock-Based Compensation (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$375,000			375,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition	3 years
Warrants Outstanding, Weighted Average ExercisePrice	$1.72			1.72
Share-based Compensation, Total	86,943	46,543
General and Administrative Expense, Total	5,739,370	10,756,150
Research and Development Expense, Total	9,092,072	8,687,406
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
General and Administrative Expense, Total	27,019	10,777
Research and Development Expense, Total	59,924		35,766
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance of Stock and Warrants for Services or Claims	820,575	785,575
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$4.25	$4.76
Director [Member] \| 2015 Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, Restricted Stock Award, Gross				179,969
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Weighted Average ExercisePrice	$7.50			7.5
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	7 years 6 months
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Weighted Average ExercisePrice	$1			1
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term	2 years 6 months
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$604,000	$489,000		604,000
Share Based Compensation Arrangement By Share Based Payment Award Non vested Options Outstanding Number	179,969	134,278
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value	$2.20	$7.91

Commitments_and_Contingencies_1

Commitments and Contingencies (Details) (USD $)	Dec. 31, 2014
2015	$210,887
2016	210,170
2017	214,297
2018	89,950
Total	$725,304

Commitments_and_Contingencies_2

Commitments and Contingencies (Details Textual)	12 Months Ended				1 Months Ended	12 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2011	Dec. 31, 2010	Aug. 22, 2014	Dec. 31, 2014	Dec. 31, 2014
	USD ($)	USD ($)	EUR (€)	EUR (€)	Intracel [Member]	Intracel [Member]	Organon [Member]
					USD ($)
Operating Leases, Rent Expense	$162,000	$160,000
Loss Contingency, Estimate of Possible Loss	150,000
Value Added Tax Payable	79,800		65,666	65,666
Royalty Rate							10.00%
Royalty Rate Payment Due There After							3.00%
Litigation Settlement, Amount	65,000
Royalty Agreement Payment Terms	5					Pursuant to the Agreement (see Note 7), the Company agreed to pay Intracel the following royalties on the Net Sales of Royalty Bearing Products (as defined): (i) 3% of net sales on the first $350.0 million of Net Sales of Colon Cancer Products occurring in the calendar year; (ii) 4% of net sales of Net Sales of Royalty Bearing Products occurring in the calendar year in excess of $350.0 million and up to and including $750.0 million and (iii) 5% of net sales of Net Sales of Royalty Bearing Products occurring in the calendar year in excess of $750.0 million.
Liabilities Assumed					$80,000,000

Related_Party_Transactions_Det

Related Party Transactions (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Apr. 30, 2014	Dec. 31, 2012
Due to Related Parties		$50,000
Due to Related Parties, Current	0	54,099
Loans and Leases Receivable, Related Parties		20,000
Executive Officer [Member]
Due to Related Parties, Current		$4,099	$20,000	$10,000

Income_Taxes_Details

Income Taxes (Details) (USD $)	12 Months Ended
Income Taxes (Details) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Current:
Federal	$206,568	$0
State	31,649	0
Foreign	0	0
Total Current	238,217	0
Deferred:
Federal	-3,932,476	-4,466,979
State	-629,774	-715,374
Foreign	-223,923	-165,845
Total Deferred (Provision)/Benefit	-4,786,173	-5,348,198
Valuation Allowance	4,786,173	5,348,198
Total Tax Provision/(Benefit)	$238,217	$0

Income_Taxes_Details_1

Income Taxes (Details 1)	12 Months Ended
Income Taxes (Details 1)	Dec. 31, 2014	Dec. 31, 2013
Income Tax [Line Items]
Income tax at statutory rate	34.00%	34.00%
Financial instruments	32.00%	-12.00%
State taxes - (net of fed)	5.00%	3.00%
International rate difference	-10.00%	-1.00%
Amortization of prepaid	-3.00%	0.00%
Change-valuation allowance - fed	-64.00%	-22.00%
All other items	3.00%	-2.00%
Effective income tax rate	-3.00%	0.00%

Income_Taxes_Details_2

Income Taxes (Details 2) (USD $)	12 Months Ended
Income Taxes (Details 2) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Income Tax [Line Items]
Start-up expenditures and amortization	$8,036,569	$5,910,419
Amortization of intangibles	4,996,993	8,631,105
Financial instruments	1,408,087	705,008
Nonqualified stock options	478,061	343,372
U.S. net operating loss	0	2,576,756
Foreign net operating loss	2,020,627	1,796,704
Total long-term deferred income taxes:	16,940,337	19,963,364
Valuation allowance	-16,940,337	-19,963,364
Total Current and Deferred Income Tax Assets/(Liabilities)	$0	$0

Income_Taxes_Details_3

Income Taxes (Details 3) (USD $)	12 Months Ended
Income Taxes (Details 3) (USD $)	Dec. 31, 2014	Dec. 31, 2013
Income Tax [Line Items]
Unrecognized tax benefits, beginning of the year	$130,000	$90,000
Decreases for tax positions related to prior years	-30,000	0
Increases for tax positions taken during the year	8,814,027	40,000
Unrecognized tax benefits, end of the year	$8,914,027	$130,000

Income_Taxes_Details_Textual

Income Taxes (Details Textual) (USD $)	12 Months Ended
Income Taxes (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Income Tax [Line Items]
Deferred Tax Assets, Valuation Allowance	-16,940,337	($19,963,364)
Unrecognized Tax Benefits	8,914,027	130,000	90,000
Deferred Tax Assets, Net, Noncurrent	2,000,000	1,800,000
Deferred Tax Assets, Operating Loss Carryforwards, Foreign	2,020,627	1,796,704
Intellectual Property [Member]
Income Tax [Line Items]
Unrecognized Tax Benefits	8,800,000
Foreign Tax Authority [Member]
Income Tax [Line Items]
Deferred Tax Assets, Operating Loss Carryforwards, Foreign	10,100,000
Foreign Tax Authority [Member] \| Minimum [Member]
Income Tax [Line Items]
Operating Loss Carry Forwards Expiration Period	2016
Foreign Tax Authority [Member] \| Maximum [Member]
Income Tax [Line Items]
Operating Loss Carry Forwards Expiration Period	2023

Supplemental_Disclosure_of_Cas1

Supplemental Disclosure of Cash Flow Information (Details Textual) (USD $)	12 Months Ended		1 Months Ended
	Dec. 31, 2014	Dec. 31, 2013	Jan. 31, 2014	Aug. 31, 2012
Interest Paid, Total	$53,279	$308,506
Common Stock, Value, Issued	3,496	3,157
Common Stock, Shares, Issued	34,962,172	31,568,629		200,000,000
Round C Warrants [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$6.05
Convertible Debt		51,159
Common Stock, Shares, Issued	5,600,000
Debt Instrument, Convertible, Number of Equity Instruments			16,822
Debt Conversion, Converted Instrument, Warrants or Options Issued	128
Round C Common Stock [Member]
Debt Conversion, Converted Instrument, Shares Issued	4,545
Debt Conversion, Converted Instrument, Amount	25,000
Bridge Loan 2012 [Member]
Debt Conversion, Converted Instrument, Shares Issued		170,540
Common Stock, Value, Issued			$300,000
Common Stock, Shares, Issued			56,075
Additional Common Stock Shares Adjusted		4,787	1,530
Bridge Loan 2012 [Member] \| Round C Warrants [Member]
Stock And Warrants Issued To Purchase Common Stock	1,363

Subsequent_Events_Details_Text

Subsequent Events (Details Textual) (Subsequent Event [Member], USD $)	3 Months Ended
In Millions, except Share data, unless otherwise specified	Apr. 03, 2015
Subsequent Event [Member]
Subsequent Event [Line Items]
Additional Paid In Capital Common Stock And Warrants	$4.20
Additional Paid In Capital Common Stock And Warrants, Share	909,091
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights adjustment Shares	25,489
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	272,727